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Abstract 
Introduction 
Syncope accounts for ≈ 2.7/1000 population/year of presentations to UK 
healthcare, a figure believed to be underestimated by up to 30% due to 
misdiagnosis.  For some patients the cause of their episode/s may remain 
unexplained. 
 
The implantable loop recorder (ILR) is effective for diagnosis of syncope and 
palpitations, with UK and European guidelines advising its use if symptoms 
are infrequent. However current follow-up regimes can lead to a slow 
diagnostic pathway for patients.  Remote monitoring technology allows 
patients to send their ILR data to their clinic 
 
Research Questions 
1) Does remote monitoring of ILRs reduce time to diagnosis and/or 
increase diagnostic yield? 
 
2) What is the impact of remote monitoring on logged events requiring 
analysis? 
 
Method 
New ILR patients at a single implanting centre were recruited. Following 
informed consent, they were randomised into control or experimental 
groups.  Patients in the control group were reviewed in the conventional 
manner with routine 6 monthly follow-ups plus additional ad hoc checks if 
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symptoms occurred.  Patients in the experimental group were asked to send 
transmissions fortnightly or following a symptom. 
 
All recordings were reviewed and classified as true or false events according 
to pre-defined criteria. Significant true event ECGs were reviewed blindly by a 
cardiologist.  All data were verified by two physiologists or a physiologist and a 
cardiologist prior to analysis.  The primary outcome variable was median time 
to clinical diagnosis. 
 
Results 
37 patients were randomised, 19 to the control and 18 to the experimental 
group.  The control group comprised 11 males and 8 females with a median 
age of 60 (36-86) years.  The experimental group comprised 10 males and 8 
females, median age 58 (36-84) years. Mann-Whitney U testing showed no 
significant differences in group demographics. 
 
Following randomisation 5526 events were logged, 1264 in the control and 
4262 in the experimental group. 28 (76%) of patients had a true event, which 
led to a diagnosis in 23 (67%) of patients.  There were 13 patients with true 
events and 10 diagnoses in the experimental group, with 15 true events and 
13 diagnoses in the control group.  Asystole was the most common event that 
led to a diagnosis, accounting for 35% of diagnoses. 
 
Kaplan-Meier analysis was used to assess the primary outcomes of time from 
event to follow-up, and time to clinical diagnosis.  Compared to the control 
group, the median time from event to follow-up was reduced from 3 to 1 week 
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(p=0.004).  Median time to diagnosis was reduced from 13 to 6 weeks 
(p=0.049) when remote monitoring was used. 
 
Conclusion 
In patients with ILR, remote monitoring significantly reduced diagnostic delay 
although the overall diagnostic yield was not increased. However remote 
monitoring resulted in a three-fold increase in logged events that required 
analysis with only 1 in 328 proving to be true events: this will have significant 
resource implications. 
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Chapter 1.  Introduction: The need and rationale for this research  
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For some patients, despite the best efforts of all healthcare professionals 
involved it can still take a long time to receive a diagnosis for the cause of 
their symptoms.  The following thesis will present the REveAL™ and 
CARElink™ (Real Care) study which aimed to ascertain if this time lag could 
be significantly reduced for a cohort of patients affected by unexplained 
syncope, palpitations, or both.  
 
1.1. Introduction 
This chapter begins by introducing the author before moving on to set the 
scene and provide the background to the thesis, informing the reader of the 
clinical problems faced by implantable loop recorder (ILR) patients.  The 
chapter will then briefly cover where and why the REveAL™ - CARElink™ 
(Real Care) study was carried out.  Reveal™ is an implantable loop recorder 
(ILR) produced by Medtronic Inc., and Carelink™ is the remote monitoring 
equipment and network used for home monitoring of implantable cardiac 
devices produced by Medtronic Inc.  Real Care was a physician - blinded 
randomised controlled trial (RCT) which recruited consecutive implantable 
loop recorder (ILR) patients. 
 
1.2. Professional interest of the author 
As a cardiac physiologist working for the National Health Service (NHS) in 
County Durham and Darlington I am privileged to work with a variety of people 
of varying ages and walks of life.  Whilst all of these people are different they 
all have something in common; an interest in the heart, diagnosed heart 
conditions, or potential heart conditions.  There are a multitude of different 
conditions that can affect the heart and various symptoms or problems that 
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can arise from a heart condition or defect.  Whilst I am interested in all 
cardiology my personal preference is in the fields of cardiac rhythm 
management (CRM), syncope, and palpitations.  It is particularly interesting 
for me when the diagnostics and management of these fields overlap. 
   
In preparation for undertaking the Real Care study and completing this thesis I 
attended a variety of courses including MSc level courses on quantitative and 
qualitative research methods, basic and applied linear regression statistics 
modules, good clinical practice in research (GCP), and beINFOrMED online 
consent training and assessment, passed the British Heart Rhythm Society 
(BHRS) exam, and completed the BHRS professional competency logbook.   
 
1.3. Lay summary of the clinical problem addressed in this thesis 
There are many reasons and factors that can cause a person to collapse 
(syncope or transient loss of consciousness (TLoC)) or suffer from 
palpitations.  Even after extensive testing using wearable external heart 
monitors or tests designed to stress the body and induce symptoms in a 
controlled environment, there may be a suspicion but not sufficient evidence 
that the cause of the problem lies with the heart.  In particular the concern is 
that the patient’s symptoms are caused by an abnormal heart rhythm.  If a 
patient’s doctor has any suspicions or the symptoms remain unexplained then 
the doctor may request the use of an implantable heart monitor called a loop 
recorder.   
 
Implantable loop recorders (ILRs) are small diagnostic devices (approximately 
the size of a standard USB memory stick) that are implanted just below the 
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skin and can monitor a patient’s heart rhythm and rate by monitoring a single 
channel of electrocardiogram (ECG) for three years or more.  Unfortunately, in 
some instances diagnosis using ILRs may be prolonged or even come after 
further injury to the patient or to people around the patient.  This could be due 
to a number of reasons, primarily that the patient may not be seen until after 
they have had their symptoms or that they may feel that they had not had 
severe enough symptoms to warrant a check of their device.  There are also 
patients that attend the department that have symptoms that may or may not 
have resulted in injury due to heart rhythm abnormalities, and on further 
investigation of the device we find that this could have been prevented.  The 
reason for this is that the patient may have had heart rhythm abnormalities 
which required intervention but were unaware of them at that time and the 
ILR’s auto detection function had recorded.   
 
New technology means that patients can send their ILR recordings from home 
and be checked more regularly by their follow-up physiologists and their 
physicians where necessary.    
 
This thesis aims to give an account of the different types of syncope and 
palpitations, leading on to explore the evidence behind the use of ILRs in the 
diagnosis of these conditions.  Once the rationale and methodology of the 
Real Care study has been provided, the thesis will examine the data collected 
from the Real Care study to establish whether the new equipment is a feasible 
option to improve patient care and reduce the time taken to confirm or exclude 
cardiac involvement as a cause for patient’s symptoms. 
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1.4. Incidence data on syncope in the UK 
The annual incidence of patients presenting with syncope in a UK setting has 
been estimated at approximately 2.7 per 1000 population (1).  With a 
population of just over 605,000 (2) in the County Durham and Darlington area, 
that would imply that around 1,634 patients within the County Durham and 
Darlington NHS Foundation Trust (CDDFT) catchment area will have a 
syncopal episode each year.  It is further suggested that 259 (16%) (1) of 
these patients will have an arrhythmic cause for their syncope.  While these 
are estimated figures on the incidence of syncope it is also reported that due 
to misdiagnosis of epilepsy and other causes of TLoC the true incidence could 
be 20-30% higher (3,4).  In a costing statement carried out by the National 
Institute for Health and Clinical Excellence (NICE) (4) it was reported that 
estimating the number of patients that require an ILR is not possible for the 
same reasons, as any numbers could potentially be an underestimation. 
 
1.5. Conventional care in the management of syncope 
Conventional care in the management of syncope varies greatly; within the 
UK there is a choice of either the National Institute of Health and Clinical 
Excellence (NICE) or the European Society of Cardiology (ESC) guidelines 
(4,5).  Whilst there is a move towards the use of the guidelines within 
cardiology and among those with a specialist interest in falls and syncope, 
there are still a large number of patients that are misdiagnosed or not referred 
for specialist assessment (3,4).  This may be as a result of there being no 
clear pathway both within the acute setting and within the wider community 
setting (1).  Therefore at the current time it is difficult to completely adopt any 
single set of guidelines and eliminate historical practice, but with that said, the 
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use of referral pathways is increasing within the falls and syncope setting 
throughout County Durham and Darlington NHS Foundation Trust (CDDFT) 
hospitals. 
 
In the CDDFT setting, falls and syncope are generally referred to and 
assessed by cardiologists or elderly care consultants with a specialist interest 
in syncope and the support of cardiac physiologists with specialisms in either 
echocardiography (echo) or cardiac rhythm management (CRM), and a 
specialist interest in syncope.  With more patients being referred to these 
specialists and the proposed introduction of a dedicated and structured Falls 
and Syncope Service within CDDFT hospitals, the shift towards following the 
pathways suggested by ESC and NICE has increased the use of diagnostic 
tools such as the ILR which is the main focus of this thesis.  More specifically 
the way in which ILR patients are followed up and managed. 
 
1.6. Conventional care and follow-up of CDDFT ILR patients 
When a patient has an ILR implanted they are routinely followed-up at five-
weeks and then every six-months.  The patient may be seen more regularly if 
they have their symptoms or if the physiologist feels that more frequent follow-
up is required, but in general patients are only seen at six month intervals. 
 
1.7. Proposed care and follow-up of CDDFT ILR patients  
It is now possible for ILR patients to have an additional piece of equipment to 
use in conjunction with their ILR which enables them to send information 
recorded automatically by, or manually on their device via phone to their 
CDDFT physiologists.  This equipment means that follow-ups can be carried 
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out more frequently without the need for patients to attend their follow-up 
department at the hospital.  It is proposed that using the home monitoring 
equipment, patients should be followed-up remotely at fortnightly intervals and 
additionally if symptoms occur. 
 
1.8. Primary and secondary research questions 
The primary research question for this thesis is: 
 
‘Can patients with implantable loop recorders have true event ECGs followed-
up sooner and can they receive a cardiac or non-cardiac diagnosis for their 
symptoms in a shorter average time if remote monitoring is employed into 
their care pathway?’ 
 
The secondary research questions for this thesis are: 
 
1. How much data is generated for review (review burden) by true and 
false recordings, both with and without the use of remote monitoring? 
 
2. Does remote monitoring impact ILR memory saturation? 
 
3. Can age or gender be used as determinants to predict diagnosis? 
 
4. What CDDFT’s ILR diagnostic yield is. 
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5. What is the trigger for true and false ILR recordings in terms of 
arrhythmia, artefacts or signal sensing and how do they breakdown into 
diagnosis? 
 
6. How long does it take to record the first true event? 
 
7. What the primary implant indications are in CDDFT hospitals. 
 
8. What is the response to diagnosis (in terms of monitoring). 
 
The primary and secondary research questions are covered in more detail in 
Chapter 3.  Real Care study aims, objectives, design and implementation.   
 
  
  
25 
 
Chapter 2.  A review of the literature 
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This chapter is split into two distinct modules, the first module (sections 2.1 - 
2.6) is not technically a literature review, rather it is a hybrid of clinical 
knowledge and supporting literature evidence.  The second module (sections 
2.7 - 2.10) follows the traditional approach and critically appraises the limited 
data available on implantable loop recorders (ILRs) in conjunction with remote 
monitoring.  Whilst unconventional, the approach is important to give the 
reader an understanding of the scope of the problem when diagnosing 
syncope and palpitations, the variety of tests used to reach a diagnosis, and 
highlight why minimising diagnostic time is important.  Once the underpinning 
knowledge and the common tests for syncope and palpitations have been 
covered the chapter will move onto the history of ILRs and the technological 
advances that have led to the availability of remote monitoring (including how 
remote monitoring has proved a valuable tool for other implantable cardiac 
devices).  In the second module the publications that were reviewed and 
appraised in order to make the REvEAL™ and CARElink™ (Real Care) study 
bridge the gap in the evidence by being as robust as possible will be 
presented.  Finally in sections 2.11 and 2.12 the literature review will be 
summarised. 
 
Due to the way in which the chapter is presented the resources explored will 
be presented in section 2.1 but the detailed search strategy for evidence 
relating to ILR in conjunction with remote monitoring will be given in section 
2.6. 
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2.1. Resources explored  
The evidence searches (Module 1) literature review (Module 2) were carried 
out using information gained from various sources. The search terms used 
were ultimately chosen by the author but discussions that led to the choosing 
were held with Professor Murphy and Jane Curry.  The main search sites 
used to locate the literature were PubMed, Medline, Ovid, Allied and 
Complementary Medicine (AMED), Excerpta Medica Database (EMBASE), 
Health Management Information Consortium (HMIC), British Nursing Index 
(BNI), PsycInfo, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) and Health Business Elite.  However Google and Google Scholar 
were also used to locate key articles and information.  Following the search 
an NHS Athens account, the CDDFT library, or the Durham University library 
was used to obtain the relevant articles and literature from a credible source 
such as a peer-reviewed journal or book. 
 
2.2. Syncope and palpitations 
Syncope originates from the Greek word Λιποθυμία, συγκοπή or sunkopѐ 
meaning to interrupt or cut off (6,7).  In medical terms syncope means 
transient (short-lived or temporary) global hypoperfusion of the cerebral cortex 
(lack of blood to the brain) which may be related to a drop in blood pressure 
or an abnormality of the heart’s rate and / or rhythm (4,5).  The term is used 
when the hypoperfusion of the brain causes loss of consciousness and 
postural tone.  Syncope is often referred to as transient loss of consciousness 
(TLoC) or ‘blackouts’.  There are fairly distinct characteristics of syncope, 
these are: 
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1. Rapid onset 
 
2. Short duration 
 
3. Spontaneous complete recovery 
 
There are four main groups into which syncope is classified with each of these 
being subdivided further (5): 
 
1. Neurally Mediated 
 
2. Orthostatic (postural) Hypotension 
 
3. Cardiac Arrhythmias 
 
4. Structural e.g. aortic stenosis or hypertrophic cardiomyopathy (HOCM) 
 
Neurally mediated syncope (NMS) has several commonly-used terminologies 
such as vasovagal or neurocardiogenic, all three of these names allude to the 
same thing, syncope caused by a decrease in blood pressure and a drop in 
heart rate that is caused by an abnormal response from the autonomic 
nervous system (8).  Under normal circumstances the blood pressure is 
constantly changing and being regulated by various complex reflex 
mechanisms (9).  If the blood pressure was to drop due to venous pooling, for 
example as result of a prolonged period of standing then this would be sensed 
by the baroreceptors (pressure sensors) in the aortic arch and carotid sinuses 
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(10).  On sensing the drop in blood pressure the correct response would be 
for the drive from the sympathetic nervous system to be increased causing an 
increase in heart rate, vasoconstriction, and reducing blood flow to non-vital 
organs to increase peripheral resistance.  Once the blood pressure is back to 
normal the sympathetic drive is reduced and the heart rate, vasculature, and 
blood flow to organs relax back to a normal state.  In most cases these 
changes are carried out in a short time frame and are therefore barely 
perceptible (11).  
 
If the system fails and an abnormal autonomic response occurs it is thought to 
be caused by a sequence of events: 
 
1. Partial emptying of the heart caused by reduced venous return due to the 
shift of fluid into the lower extremities. 
 
2. Hypercontractility of the ventricles as part of the normal sympathetic 
response as the system attempts to increase cardiac output. 
 
3. The mechanoreceptors (stretch receptors) in the heart are paradoxically 
stimulated as a result of the under-filled heart being hypercontractile. 
 
4. The abnormal impulses from the stretch receptors are transmitted to the 
tractus nucleus solitarius which initiates the parasympathetic (vagal) drive 
and inhibits the sympathetic drive. 
 
5. This results in bradycardia, increased hypotension, and syncope. 
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While this is the traditionally accepted pathway for NMS (12), evidence 
suggests that there are various other contributory factors such as 
neurohormonal sympathetic inhibition or the possibility that carotid and aortic 
baroreceptor function on the sympathetic nervous pathways is impaired in 
patients predisposed to NMS (13). 
 
Orthostatic Hypotension (OH) is essentially the same as NMS, however it has 
specific criteria for diagnosis and can, if asymptomatic, precipitate a NMS 
attack (14).  The diagnostic criteria recommended in Europe by the European 
Federation of Neurological Societies (EFNS) are a systolic BP drop of 
≥20mmHg or a diastolic BP drop of ≥10mmHg, within 3 minutes of posture 
change from supine / sitting-to-erect (15).  
 
The final two forms of syncope, viz; cardiac and structural, do to a large extent 
cross over but in general terms cardiac syncope refers to isolated electrical 
abnormalities of the heart that cause a fast rhythm (tachycardia) or a slow 
rhythm (bradycardia).  Both could have ischaemic or non-ischaemic causes 
(16).  In the strictest of terms a bradycardia is considered to be a heart rate 
below 60 beats per minute (bpm) (17), in practice however a bradycardia is 
not considered to be significant unless the heart rate falls below 40bpm during 
symptoms (16). 
 
There are several types of bradycardia though they tend to come under two 
main headings (18,19): 
1. Sick Sinus Syndrome (SSS) also commonly referred to as sinus node 
dysfunction (SND) 
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(i.) Sinus bradycardia – The heart rate is below 60bpm but the conduction 
of impulses through the heart are following the normal pathways. 
 
(ii.) Sinus arrest – This is when the sinoatrial (SA) node fails to depolarise, 
the time that the node is in an arrested state can vary from one beat to 
30 seconds or more. 
 
(iii.) SA exit block – This is when the cells of the sinus node fails to conduct 
to the surrounding atrial tissue, this block could be of the first degree 
meaning that its conduction is delayed, second degree meaning that 
every other impulse is blocked or third degree meaning that every 
impulse is blocked. 
 
2. Atrioventricular (AV) conduction defects 
 
(i.) First degree AV block – The conduction between the atria and the 
ventricles is delayed for longer than the normal time of 120-200ms. 
 
(ii.) Mobitz I second degree AV block – the time taken for conduction 
between the atria and ventricles prolongs with each beat until the atrial 
impulse is blocked at the AV node. 
 
(iii.) Mobitz II second degree AV block – 2:1, every other atrial impulse is 
blocked at the AV node. 
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(iv.) Third degree AV block or complete heart block – There is no 
conduction through the AV node and the heart is reliant on an escape 
rhythm (a rhythm initiating from a different focus in the heart) for 
depolarisation. 
 
While all of the above defects have been described in terms of conduction 
through the atria and ventricles it may be prudent to mention that conduction 
of the heart is often described in terms of the depolarisation and repolarisation 
of the atria and ventricles as seen on the surface ECG.  In nearly all cases the 
Q from PQRST is dropped as there is not always a Q wave present and 
measurements of AV conduction are described as PR interval. 
 
All heart rates above 100bpm are considered to be a tachycardia.  However 
not all tachycardias are abnormal and the heart rate may have increased as a 
normal physiologic response due to exercise or stress which makes the onset 
of a tachycardia an important factor as most tachycardias with gradual onset 
are physiological and therefore not problematic.  Tachycardias with sudden 
onset in most cases are non-physiological.  The origin of tachycardias is 
generally speaking from the atria or the ventricles, supraventricular or 
ventricular respectively.  While supraventricular tachycardias are rarely life 
threatening in adults they can make patients feel particularly unwell, with 
symptoms including but not limited to; shortness of breath, dizziness or 
syncope, and on occasion patients also report simply having a sinking feeling 
in their chest or stomach.  Tachycardias with ventricular origins such as 
ventricular tachycardia (VT) and ventricular fibrillation (VF) are more 
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commonly related to haemodynamic compromise and become fatal if 
untreated.   
 
Palpitations are defined as an awareness of the heartbeat, this can be in the 
form of a fast, irregular, hard or missed beat or beats.  Palpitations are often 
described by patients to be felt in the chest, neck, throat or stomach (20).   
As previously mentioned tachycardias commonly come under the categories 
of atrial or ventricular however there can also be tachycardias originating from 
the junction between the atria and the ventricles, these are simply referred to 
as junctional tachycardias.   
 
In the category of atrial tachycardias there is: 
 
1. Atrial fibrillation (AF) – In AF evidence suggests (21) that impulses 
initiating in the pulmonary veins cause the cells in the atria to fire at 
random in a disorganised and irregular fashion.  The disorganised 
impulses are then conducted through the AV node at random giving rise 
to the term irregularly irregular rhythm.  As the term irregularly irregular 
rhythm implies, there is no pattern in the conduction through the AV node.  
On the surface ECG AF appears as a completely random array of QRS 
complexes with an erratic baseline.  If the AV node is intact then 
ventricular rates of patients in AF can be up to or in excess of 200bpm.  In 
Figure 1 - The electrical pathway for normal sinus rhythm and AF can be 
seen. 
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Figure 1 - The electrical pathway for normal sinus rhythm and AF 
 
(Permission requested from Dr O R Segal at www.oliversegal.com August 
2016) 
 
Atrial Flutter – There are several types of atrial flutter which are 
classified as typical or atypical.  For the purpose of this explanation the 
focus will be on typical atrial flutter.  The atrial rate in atrial flutter is 
commonly 300bpm but can vary between 200 – 350bpm, the 
ventricular rate is governed by the AV node.  In the majority of cases 
there is some degree of AV block, this is normally 2:1 or 3:1, giving 
ventricular rates of 100-150bpm.  The impulse travels through the right 
atrium along a well-defined pattern or macro re-entrant pathway around 
the tricuspid annulus.  The circuit in atrial flutter is made stable by 
anatomical blockades formed by the vena cava, the crista terminalis 
and the coronary sinus.   
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Figure 2 - Anatomical structures creating the atrial flutter pathway 
 
 
(Permission requested from Cardiology Heart and Dr O R Segal August 2016) 
 
2. AV Nodal Re-entrant Tachycardia (AVNRT) – For AVNRT to exist there 
has to be a fast pathway and a slow pathway.  The exact mechanism is 
still not fully understood but electrophysiological (EP) studies have 
significantly improved understanding and led to the widely accepted 
explanation (22).  From EP evidence and historical models, the impulse 
pathways of AVNRT go around or through the AV node (23).  The most 
common type of AVNRT uses the slow-fast route meaning that the 
impulse travels down the slow pathway and initiates the ventricular 
contraction but a portion of the impulse continues to travel back up the 
fast pathway as the impulse comes back up the fast pathway it initiates 
depolarisation of the surrounding atrial cells which in turn blocks the 
intrinsic P wave and the impulse continues back down the slow pathway.  
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Figure 3 - Schematic representation of the AVNRT electrical pathway 
shows the theory behind the slow-fast AVNRT.  
 
Figure 3 - Schematic representation of the AVNRT electrical pathway 
 
 
3. AV Re-entrant Tachycardia (AVRT) – AVRT pathways operate on a 
similar principle to AVNRT except that the re-entrant pathways are 
classified as macro circuits and that they cross the electrically inert fibrous 
divide between the atria and the ventricles via an accessory pathway.  
Accessory pathways in most forms of AVRT conduct in the retrograde 
meaning that the signal travels from the ventricles to the atria and are 
blocked in the anterograde (atria to ventricles) direction.  AVRT is initiated 
by an atrial premature beat, the accessory pathway is refractory when the 
impulse reaches it so the only conduction to the ventricles is through the 
AV node.  By the time the impulse has travelled through the ventricles the 
accessory pathway is recovered and the impulse re-enters the atria and 
the tachycardia begins.  This type of tachycardia normally has a narrow 
complex (this usually refers to a QRS measurement on the surface ECG 
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of 80 – 120ms) unless there is a pre-existing or a functional bundle branch 
block (BBB).  P waves in AVRT are sometimes visible as a notch in the 
QRS or just after the QRS in the early ST segment and will be on a 1:1 
basis.  The rate of an AVRT is usually between 120 and 250bpm.  In true 
AVRT the 1:1 conduction will not be affected by drugs or manoeuvres 
such as the Valsalva, which affect AV conduction speed.  If the ventricular 
rate but not the atrial rate is affected then it is more likely to be an atrial 
tachycardia or atrial flutter. 
 
2.3. Common tests used for syncope and palpitation diagnosis 
There are a few tests that are commonly used in diagnosing or attempting to 
diagnose both syncope and palpitations that occur infrequently, but the use of 
these tests are not always the most appropriate or cost effective (3,5,14,24).  
The terms infrequent and infrequently refer to symptoms that occur less than 
fortnightly.  While the use of the following tests are common there have been 
pathways developed and tested over recent years which suggest that with a 
thorough history and basic cardiovascular assessment then the tests need not 
be done.  If there is still doubt surrounding the origin of the problem then an 
ILR should be implanted (1,3,5,16).  However it is important to cover the tests 
here as they are still widely used in clinical practice. 
 
Possibly the most common test for infrequent syncope or palpitations is the 24 
hour - seven day Holter monitor or ambulatory ECG recording device.  The 
devices are named Holter monitors after the creator Norman Holter who first 
invented the device in the 1950s and introduced it into clinical use in the 
1960s (25,26). A Holter monitor is capable of recording several channels of 
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continuous ECG, often two or three channels depending on the duration of 
recording.  The monitors can record for up to seven days with a single battery 
and memory card. The device is attached to the patient for the selected 
amount of time using adhesive electrodes.  The patient is then free to carry 
out their normal day-to-day activities providing that they do not submerse the 
device in water, i.e. no baths, showers, or swimming etc.  Figure 4 shows a 
Spacelabs Healthcare Lifecard CF® digital Holter monitor. 
 
Figure 4 - Spacelabs Healthcare Lifecard CF® digital Holter monitor 
 
(Permission requested from Spacelabs Healthcare UK September 2016) 
 
Once the device is returned the recording is analysed.  The analysis is carried 
out using specialist software by physiologists or specially trained healthcare 
professionals and a factual report is produced.  Whilst the Holter monitor is a 
valuable tool it is not without its flaws.  If the appropriate skin preparation is 
not carried out or the stickers become dry then the recording can be very 
artefactual which can in extreme cases render the recording unusable.  Other 
problems that can occur are the disconnection of leads whether accidental or 
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deliberate, or in some cases the device is actually dismantled.  There is also 
the problem of symptoms not occurring while the monitor is attached.  In some 
instances the test is repeated multiple times with no diagnostic value. 
 
The next diagnostic tests to be covered are the external loop and cardiac 
event recorders.  Like Holter monitors there are several makes and designs of 
external loop recorder and cardiac event recorder.  The principle is similar for 
both with the only differences being; 
 
1. The duration of recordings and the capacity of the device. 
 
2. The way in which recordings are made. 
 
The first of these points is relatively self-explanatory but the second may 
require some explanation.  In the case of cardiac event recorders the devices 
record a rhythm strip of one to two channels of ECG.  The duration of these 
strips varies from manufacturer to manufacturer and in many cases is 
programmable.  The method of recording can also vary, there are devices 
which attach in the same way as a Holter monitor and there are those that 
have metal studs on the outer casing that is held against the chest during a 
symptom episode.  In both cases however cardiac event recorders only record 
if activated externally.  External loop recorders are attached to the patient 
using adhesive electrodes and incorporate all of the features of the cardiac 
event recorder but also monitor on a continuous loop.  This means that they 
can record variations in heart rhythm and rate without the need for outside 
activation (27).  Most modern external loop recorders and cardiac event 
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recorders are capable of recording for up to one month on each set of 
batteries.  Unfortunately many patients suffer reactions to the adhesive 
electrodes after just a few days.  Whilst every effort is made to prevent this by 
repositioning stickers and removing devices for baths and showers, the 
devices can become uncomfortable and even begin to interfere with people’s 
lives during prolonged monitoring. Figures 5 and 6 show a Reynolds Medical 
(now Spacelabs Healthcare) Cardio Call and a Novacor Rtest respectively.  
The Cardio Call can be used as either a monitor that has the metal studs 
placed against the skin during a symptom episode, or as a wired monitor but 
will only record if activated externally.  The Rtest has the ability to record 
strips on external activation but will also record rhythm strips if programmable 
parameters are met. 
 
Figure 5 - Spacelabs Cardio Call cardiac event recorder 
 
(Permission requested from Spacelabs Healthcare UK September 2016) 
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Figure 6 - Novacor Rtest external loop recorder 
 
(Permission requested from Novacor UK Ltd. September 2016) 
 
The last diagnostic test to be covered is the head up tilt (HUT) test.  The HUT 
was the result of several studies carried out in the 1800s, these studies 
culminated with the work of Hill (1895).  While others had used positional 
changes in their work, Hill was the first to use a table and outstretched limbs 
(28).  The research around syncope continued into the early 1 00s but the 
ne t milestone for the H T was not until 1    when researchers used 
university students tilted to  0 with or without the use of sodium nitride to 
induce syncope (29).  HUT as a diagnostic tool for unexplained syncope was 
not reported to be clinically useful until the mid 1980s, some 90 years after its 
inception (30).  By the early 1990s HUT was widely accepted as a clinically 
useful tool but due to the variety of techniques giving a variety of sensitivity 
and specificity results the American College of Cardiology (ACC) was 
prompted to review the evidence and produce one of the first expert 
consensus documents on HUT (31). 
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The principal of the HUT is simple, and while predominantly aimed at NMS it 
is also effective in patients with other forms of reflex syncope and patients 
with sick sinus syndrome (SSS) (32).  The attraction to the use of HUT is that 
symptoms can be reproduced in a safe and controlled environment.  If 
patients are held at an angle of between  0 –  0 then venous pooling will 
occur and venous return will reduce as a result of the orthostatic stress and 
immobilisation.  If the test is positive meaning that symptoms are reproduced, 
then following the period of stress, hypotension and a drop in heart rate will 
occur due to impaired vasoconstrictor capability, withdrawal of sympathetic 
nervous stimulation and hyperactivity of the vagal tone (33).   HUT in general 
can be classified as provoked or unprovoked.  There is also lower body 
negative pressure (LBNP), essentially LNBP induces the same physiologic 
response as HUT.  However the venous pooling in the vasculature of the 
pelvis and legs is induced by applying sub atmospheric pressure around the 
lower body (34).  Provocation can be carried out using several pharmaceutical 
methods, Isoproterenol and nitroglycerine are the most common drugs used 
(5).   
 
There are two main protocols used for HUT; the Italian protocol and the 
Newcastle protocol (4,5,35,36).  However in the 2008 Newcastle protocol 
update there was a consensus between the two protocols (33).  In the CDDFT 
HUT service we use a hybrid of the Newcastle protocols (33,36) and the 
orthostatic hypotension (OH) framework (37), incorporating the active stand 
and the HUT. 
 
  
43 
 
Patients are asked to fast for four to six hours prior to the test.  On arrival to 
the department they are taken in to the test room, the test is fully explained 
and the history of their symptoms is taken again.  Once the patient is happy 
and has given consent to proceed they are attached to the monitoring 
equipment and strapped to the tilt table in the supine position.  Once the 
patient has rested for approximately 15 minutes and the equipment has been 
validated (the process of ensuring that the beat to beat and oscilometric blood 
pressure are correlated) the patient is angled to  0 for two minutes.  After two 
minutes the patient is returned to the supine position for a further two minute 
rest period.  The ne t stage is the H T, the patient is tilted to the  0 position 
where they remain for 20 minutes.  If the test has not achieved a positive 
result after the initial 20 minutes at  0 then providing there are no contra-
indications they are given  00 g of glyceryltrinitrate (GTN) sublingually.  The 
patient will then remain at  0 for a further 1  minutes.  If there are contra-
indications to GTN then an unprovoked H T will be carried out.  In the 
unprovoked H T patients remain at  0 for  0 minutes.  In both cases the 
‘healthy’ patient should be able to maintain blood pressure and 
consciousness. 
 
Whichever test is carried out, the test is ended if the patient suffers a 
symptomatic episode, feels unable to continue with the test, or the test 
reaches its endpoint.  In patients over 50 years of age there is another 
element to the test.  Providing there are no contra-indications and the patient 
gives consent then left and right carotid sinus massage (CSM) will be carried 
out in the supine and erect positions with two minute intervals between each 
massage.  CSM is a test designed to assess the presence of carotid sinus 
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syndrome (or hypersensitivity).  By massaging the carotid sinus for between 
five and ten seconds the pressure caused by the massage mimics an 
increase in blood pressure, the resultant autonomic response causes a 
transient increase in vagal tone (reducing heart rate) and reduction in 
peripheral vascular resistance due to dilation of the blood vessels.  The key 
word here is transient.  In individuals with carotid sinus hypersensitivity, the 
effect is still considered transient but is markedly more significant.  In 
situations where carotid sinus hypersensitivity is present the response to CSM 
can produce significant bradycardia / asystole (cardio inhibition), marked 
hypotension (vasodepression), or both (38). 
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Figure 7 - HUT table and monitoring system 
 
(Permission requested from CNSystems Austria May 2017) 
 
2.4. Implantable loop recorders. 
The implantable loop recorder (ILR) whilst not considered an uncommon test,  
it is considered to be an underutilised tool in the diagnosis of syncope and 
palpitations (3,5,4,39,40).  As ILRs are the main focus of this thesis they are 
covered separately in this section and not included in 2.3.   
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ILRs are small diagnostic devices that are capable of recording a single 
channel of electrocardiograph (ECG) over an extended period of time (3).  
The current mainstream devices Medtronic Inc.’s Reveal™ DX and XT shown 
in Figure 8 are comparable in size to a USB memory stick measuring 62 x 19 
x 8mm with a volume of 9cc and a weight of 15g.  The main casing of the 
Reveal™ is constructed using titanium with a polyurethane and silicone 
header.  The whole construction with the exception of the two 43mm2 (surface 
area) electrodes is then hermetically sealed and encased in parylene.  The 
effective distance between the electrodes is  0mm.  Reveal™ devices are 
powered by a 3.6 volt lithium thionyl chloride battery with a projected longevity 
of three years (41). 
 
Figure 8 - Reveal™ XT and DX Dimensions 
 
The ILR device is implanted using local anaesthetic in the subcutaneous 
tissue of the left hemithorax (42).  The indications for the use of ILRs include, 
but are not limited to, the diagnosis of unexplained syncope or transient loss 
of consciousness (TLoC) where cardiac involvement such as an arrhythmia is 
suspected or indicated but not confirmed (43), palpitations, and observation-
62mm 
8mm 
 
19mm 
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guided management of atrial fibrillation (AF) patients (3).  In many cases the 
use of ILRs comes after the repeated use of tests described earlier in this 
chapter such as Holter monitoring, external loop recorders or HUT; however in 
some cases, the European Society of Cardiology (ESC) and The National 
Institute for Health and Clinical Excellence (NICE) suggest early use of ILRs 
for symptoms considered to be infrequent (less than once every two weeks).  
Both NICE and the ESC state that after initial assessment and subsequent 
cardiovascular assessment by a suitable person or physician, if 
TLoC/syncope occurs infrequently and is believed to be due to cardiac 
arrhythmia, or remains unexplained then an ILR should be employed (4,5).  
Results from the place of Reveal™ in the care pathway and treatment of 
patients with unexplained recurrent syncope (PICTURE) study demonstrated 
a high diagnostic yield from ILRs and suggested that the devices were under-
utilised in clinical settings and that better adherence to guidelines could 
reduce the wasted tests and consultations that many patients go through (40).  
It has also been suggested that if ILRs are used as laid out in the guidelines 
produced by NICE (4) in the UK, they are cost effective (39).  While ILRs are 
considered an effective tool the recorders suffer from memory saturation, 
meaning that events are logged but not available for analysis, this is in part 
due to over-sensing and under-sensing (43).  The current method of in-office 
follow-up promotes saturation and potentially prolongs diagnosis and/or 
treatment (44,45).  
 
Delaying treatment can have an impact for the patient in several ways.  In 
terms of driving a ban of four weeks extending indefinitely until the cause is 
identified can be imposed.  The reason for the stringency is that syncope is 
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two to three times more likely to cause a road traffic collision than epilepsy 
(46).  There is also evidence that prolonging diagnosis can lead to further 
symptoms and hospitalisations (47) and anecdotally patients report impacts 
upon their quality of life, stating that they do not want to leave their house or 
that they cannot go and do day to day activities for fear of symptom 
recurrence.  
 
2.5. The history and technical advances of implantable loop recorders 
In County Durham and Darlington NHS Foundation Trust (CDDFT) hospitals 
only Medtronic Inc.’s Reveal™ ILRs are currently implanted.  For this reason 
the focus of this history was on those devices but competitors’ devices were 
not overlooked and will be mentioned herein.  Anecdotally the Reveal™ family 
of ILRs has dominated the ILR market, and while other manufacturers have 
tried to compete such as St Jude Medical with their Confirm™ device and 
Biotronik’s BioMonitor™ it appears unlikely that this dominance over the 
market will be threatened any time soon, certainly within the North East of 
England. 
 
The first published report of ILRs being used in clinical practice was published 
in the late nineties by Krahn et al. (48), the research for their paper involved 
ILRs that were implanted between 1992 and 1994.  The ILRs used in the 
studies of the early nineties were manufactured by Medtronic Inc. and were 
comparable in size to a single chamber  pacemaker (48), much larger than the 
Reveal™ ILR devices that were launched in 1  8 also by Medtronic Inc.  The 
original device had longevity of 14 months and only recorded when activated.   
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The Reveal™ was replaced in 2000 by the Reveal™ Plus. Both the Reveal™ 
and the Reveal™ Plus devices were capable of recording  2 minutes of single 
lead ECG and the introduction of the Reveal™ Plus maintained the 1  month 
longevity.  However, the Reveal™ Plus had the additional feature of 
automated recording.  This feature was a huge step forward for these devices 
as it meant that even if the manual activator was not used during a 
symptomatic episode or if patients were non-compliant with the activator but 
an arrhythmia was present then there was still a chance that the information 
would be collected (49).  As with all new advances in technology, the 
automatic recording function was not welcomed by everyone.  Some felt that 
the automated recordings did not improve a patient’s diagnostic journey and 
that it increased the clinical workload with analysing false recordings or 
recordings containing artefacts (50,51). 
 
The ne t device in the Reveal™ family, the Reveal™ DX was not introduced 
until 2007.  The DX brought with it several improvements;  sensing and 
detection enhancements which reduced false and artefactual recordings, 
improved longevity of up to 36 months and larger recording capacity of 49.5 
minutes.  As with all ILRs the device memory could be overwritten if the 
patient used the manual activator after or during a symptom, or erased by the 
physiologist during follow-up so that the device is ready to record anew (52). 
 
In 200  the Reveal™ XT was launched.  This introduced the AF detection 
algorithm and the cardiac compass which gives the clinical team more 
information such as heart rate and AF trend data on a rolling 14 month 
window. 
  
50 
 
Both the Reveal™ DX and XT are still available and in February 201  the 
Reveal™ LINQ was added to the Reveal™ family tree.  The LINQ is smaller 
than all of its predecessors by 87% and has enhanced capabilities such as 
wireless transmission and larger memory, of up to 57 minutes: all whilst 
maintaining the three year longevity (53).   nfortunately the Reveal™ LINQ is 
not yet in mainstream use. In our Trust this is in part down to the relatively 
high cost. Currently the LINQ is more than double the price of the XT.  The 
overall progression of Medtronic Inc. ILRs can be seen in Figure 9 - Timeline 
of Medtronic™ Reveal™ device family 
 
Figure 9 - Timeline of Medtronic™ Reveal™ device family 
 
 
 
 
 
 
The Reveal™ DX and XT ILRs are capable of storing   .  minutes of 
recording which is broken down into three, seven and a half minute manually 
activated recordings and 27 one minute automated recordings.  It is worth 
noting at this point that the configuration of the manually activated recordings 
can be altered to record two, ten minute recordings or one, 15 minute 
recording.  Manual recordings collect ECG for a period of time both before the 
ILR was activated and after.  In all cases the majority of the recording is 
collected retrospectively, either six and a half minutes, nine minutes or 14 
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minutes depending upon the manual recording option chosen.  In all cases of 
manual recording one minute of recording will be stored post activation. 
The automated recordings are stored as one of four or five categories 
(dependent upon device, i.e. DX or XT); 
 
1. Fast ventricular tachycardia (FVT) 
 
2. Ventricular tachycardia (VT) 
 
3. Bradycardia (Brady) 
 
4. Asystole  
 
5. Atrial tachycardia / Atrial fibrillation (AT / AF) (not available on the DX 
model) 
 
The automated storage parameters are adjustable allowing the device to be 
tailored for the patient’s or the clinician’s requirements.  An e ample of this 
tailoring would be reducing the rate at which the device determines a FVT or a 
VT or reducing the number of beats required before a device can classify a 
rhythm. The typical CDDFT Reveal™ XT device parameters are shown in 
Table 1 - CDDFT ILR implant typical settings, a Reveal™ DX would be setup 
in the same way without the AT/AF setting as it is not available on the DX. 
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Table 1 - CDDFT ILR implant typical settings 
 Detection Rate 
(bpm / ms) 
Detection 
Duration 
FVT 176 / 340 12 / 16 beats 
VT 150 / 400 12 beats 
Bradycardia 40 / 1500 4 beats 
Asystole - 3 sec 
AT / AF - >6 mins 
 
The detection rate column in the table refers to the heart rate in beats per 
minute or R-R interval in milliseconds before the device can classify an auto 
recording.  The detection duration is the number of beats or in the case of 
asystole the duration required at the detection rate in order for the device to 
record an automated recording. 
 
In addition to the settings in Table 1 there are several other settings that are 
routinely switched on either prior to implant during the device set – up or 
shortly after device activation, ectopy reject is turned on and the detection 
enhancement settings are turned on to their default values. 
 
It is worth mentioning the follow-up procedure at this point, however it is only 
covered lightly as the process concerning significant recordings is covered in 
more detail in section 3.14 Procedure for all follow-ups with significant ECGs 
on page 84.  At all CCDFT ILR follow-up appointments patients are asked 
how they have been and if they have had any symptoms, the device is then 
interrogated and recordings are reviewed.  Once the appropriate printouts of 
ECGs, ECG logs, and heart rate trend information has been printed and 
saved the device memory is wiped so that the device is ready to start 
collecting data again.   
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2.6. Remote monitoring 
A recent advance in ILRs has made the use of remote monitoring available as 
an alternative or as a supplement to in-office follow up.  There is readily 
available research on the effective use of remote monitoring with other 
implantable cardiac devices such as implantable cardioverter defibrillators 
(ICDs), cardiac resynchronisation therapy (CRT) devices and pacemakers 
(PMs) (54,55,56,57,58).  A study by Raatikainen and colleagues (57) found 
that remote monitoring in the ICD patient population was a safe and cost-
effective alternative to in office follow-up.  Other studies found that in patients 
with ICD and CRT devices, not only can remote monitoring improve the 
management of arrhythmias but it can also reduce heart failure 
hospitalisations, appropriate and inappropriate ICD shocks, and potentially 
reduce mortality (54,59,60).  Furthermore it has been shown that using the 
data recorded on pacemakers (particularly relating to atrial arrhythmias, 
remote monitoring can reduce stroke occurrence and hospitalisations (60). 
One of the pivotal moments for remote ICD monitoring that led to it being 
considered valuable for patients and clinical staff was the recommendation by 
the US Food and Drug Administration (FDA) that remote monitoring is a valid 
safety tool (61,62).  The recommendation was due to problems with ICD lead 
systems such as St Jude’s Riata family of leads or Medtronic’s Sprint Fidelis 
lead.  The lead problems were different for both manufacturers, for St Jude 
the problem was insulation failure (62) and for Medtronic it was lead fracture 
(61).  However both had the same potentially serious risks attached the most 
serious risk was death, caused by failure of the device to deliver therapy.  
Other issues related to these lead problems were inappropriate shocks which 
are associated with not only increased mortality but also psychological 
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implications (i.e. depression and anxiety), and abnormal sensing and pacing 
(59,60,61,62,63).  Furthermore, the latest Heart Rhythm Society guidelines for 
pacemakers, ICDs, and CRTs now stipulate that the devices should be 
routinely monitored via remote systems and that the equipment is best 
prescribed within two weeks of implant (64).  
 
Remote monitoring has been trialled in other areas of medicine, in diabetes 
for example as a viable form of controlling blood glucose and activity for 
patients with type two diabetes (65), and for preventing nocturnal 
hypoglycaemic and hyperglycaemic events in children with type one diabetes 
(66) but the evidence suggested that further research and development was 
required to improve compliance and efficacy.  Recently a closed loop system 
that automatically adjusts insulin via a smartphone app which also transmits 
data to clinicians or caregivers was trialled with promising results but again 
further research is required (67). 
 
Due to the infancy of remote monitoring in ILRs there is still very limited data 
available (44), which will lead us on to the focus of this literature review.  
However it is first necessary to provide an understanding of the way in which 
remote monitoring works.  The example used will be the Medtronic Inc. 
version of remote monitoring the Carelink™ network. 
 
The Carelink™ network uses RF telemetry and bluetooth™ technology to 
retrieve information from a patient’s device.  The information is then 
transmitted across the mobile 3G network to a secure web server.  Once the 
information is on the server it can be accessed by the patient’s physiologist or 
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cardiologist securely by way of them logging in to a secure website.  In the 
instance of an ILR all information that would be available in the clinic is 
available online, including trend tables, device parameters and ECGs.  Data 
for European patients is stored on a server in Limburg, The Netherlands.  This 
means that the use of this data is governed by the same data protection laws 
as in the UK. 
 
The process for patients to send their information is simple; Patients press a 
single button on their transmitter and follow the on-screen instructions.  Figure 
  shows the pictorial instruction leaflet supplied with the Carelink™ 
equipment.  The colour illustrations match the illustrations shown on the 
transmitter whose screen is also in colour. 
 
Once the information is transmitted to the server by the patient it is held until 
accessed by the follow-up team.  In the case of CDDFT hospitals this is done 
daily in the morning and afternoon.  Additional checks for downloads are 
carried out if a patient calls to notify the staff that they have had a symptom 
and sent a transmission or if patients call and are asked to send a 
transmission. 
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Figure 10 - Carelink™ instructions 
  
  
                                         
(Permission requested from Medtronic Inc. August 2016) 
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2.7. Search strategy for previous research relating to implantable loop 
recorders in conjunction with remote monitoring 
As with the previous sections of this review, all available resources were 
utilised in attempting to find relevant articles.  PubMed, Medline, Ovid, Allied 
and Complimentary Medicine (AMED), Excerpta Medica Database 
(EMBASE), Health Management Information Consortium (HMIC), British 
Nursing Index (BNI), PsycInfo, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and Health Business Elite were the primary search tools 
and databases then a search of Google Scholar was carried out as a back-up.  
 
The search for key articles was carried out with the initial search term 
‘implantable loop recorder (OR) ILR (OR) implantable cardiac monitor (OR) 
ICM’ this was followed by a separate search for ‘remote monitoring’.  This 
search was useful in highlighting the numerous applications for remote 
monitoring outside of the cardiology environment but was far too broad.  
Therefore the search was repeated as ‘remote cardiac monitoring’ then 
‘remote monitoring (AND) cardiac devices (OR) implantable loop recorders 
(OR) ILR (OR) implantable cardiac monitors (OR) Reveal (OR) Carelink’.  
After the initial search the ICM abbreviation was removed as it is used for too 
many other applications i.e. intensive case management, Institution of 
Chinese Medicine, ischaemic cardiomyopathy, in chair movement, and 
Institute for Complementary Medicine.  The search including ‘ICM’ returned 
over 1 ,000 articles whereas the search minus ‘ICM’ returned a more 
manageable 2,300 articles.  Details of the search strategy and number of 
results can be found in Table 2 - Search databases, terms, and number of 
results.
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Table 2 - Search databases, terms, and number of results 
Database(s) Search term No. of 
results 
AMED, BNI, CINAHL, EMBASE, 
HBE, HMIC, Medline, PsycINFO,
PubMed 
(Implantable loop recorder OR ILR OR implantable cardiac monitors OR ICM).ti,ab 17,269 
(Implantable loop recorder OR ILR OR implantable cardiac monitors).ti,ab 2,315 
(Remote monitoring).ti,ab 8,837 
(Cardiac remote monitoring).ti,ab 389 
(remote monitoring AND (cardiac devices OR implantable loop recorders OR ILR 
OR implantable cardiac monitors OR Reveal OR Carelink)).ti,ab 
536 
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Inclusion criteria for articles / papers: 
 
1. Article / paper must be directly related to the use of remote monitoring 
in conjunction with ILRs. 
 
2. Article / paper must be written in or translated to English. 
 
After the search had been altered to remove the ‘ICM’ abbreviation a brief 
review of all the returned titles of the articles / papers was carried out.  If a title 
suggested relevance then the abstract was also reviewed and in some cases 
the full text was reviewed.  All articles that did not stipulate in the title what 
type of device was used or whether remote monitoring was used then the 
abstract was reviewed.  The search was carried out using the term individually 
and in conjunction with one another to ensure nothing pertinent to the 
investigation was missed.  When the final search was carried out, of the initial 
533 articles there were 129 duplicate articles which were removed, this left 
407 articles.  Once all of the 407 articles had been reviewed and the inclusion 
criteria applied, only three articles were identified.  In addition to the three, 
there were previously published conference proceedings appearing on 
searches, however on attempting to obtain these publications they could not 
be obtained.  Even going direct to the journals involved became a fruitless 
exercise as the supplements that had published the work had been removed 
for reasons unknown.  Initially the lack of publications was a shock, but 
considering the narrowness and relatively young age of this topic, perhaps 
this is an expected result.   
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The three relevant articles returned as of May 2017 were: 
 
1. Remote electrocardiographic monitoring with a wireless implantable loop 
recorder: minimising the  data review burden (45) 
 
2. Effectiveness of remote monitoring in the management of syncope and 
palpitations (44) 
 
3. Effectiveness and safety of remote monitoring of patients with an 
implantable loop recorder (68) 
 
All three of the reviewed and appraised articles were written by authors with 
affiliations to well-known institutions and were published in peer-reviewed 
journals. 
 
2.8. Article One - Remote electrocardiographic monitoring with a 
wireless implantable loop recorder: minimising the data review burden 
The first article by Arrocha and colleagues (45) reported the findings of ‘The 
pilot study of the Sleuth® implantable ECG monitoring system (P LSE)’.  
PULSE was a non - randomised, prospective pilot study.  It was designed to 
gain proof of concept for a novel wireless ILR with a non-patient interactive 
remote monitoring system in a clinical setting therefore did not incorporate a 
control group. 
 
Whilst the equipment used in this study was significantly different to the 
Medtronic Inc. equipment, in terms of device size and patient interaction, it 
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was the first study to look at remote monitoring of ILRs and it raised some 
interesting questions surrounding the burden that increased follow-up of ILRs 
will create for clinical staff, regardless of whether follow-up is remote in nature 
or not. 
 
The PULSE study recruited 40 patients from four centres with unexplained 
syncope suspected to be cardiac in origin of whom the most recent 12 lead 
ECG showed normal sinus rhythm.  Unfortunately the article did not state if 
the patients were recruited consecutively or if there was any form of further 
inclusion or exclusion criteria applied to participants.  The omission of any 
form of selection criteria or selection process for the PULSE study raises the 
question of selection bias.  The report only stated that the participants’ last 12 
- lead ECG showed normal sinus rhythm plus or minus ectopic beats; it did 
not report any other tests that were carried out and raises the question of 
whether the researchers were allowed to select their patients.  
 
The paper states that the devices were programmed at the physicians’ 
discretion but the analysis criteria was set out by the researchers: the paper 
does not give any further details as to what parameters were at the 
physician’s discretion.  The researchers chose for their automated detection 
for bradycardia only one beat below 40bpm as a trigger and six out of eight 
beats above 150bpm as a tachycardia.  The manual review was perhaps a 
little more stringent but in the majority of cases in our clinical practice for 
example a bradycardia would not be considered significant unless it was less 
than or equal to 30bpm for four or more beats.  Whilst this may miss some 
arrhythmias the primary function of a loop recorder is to correlate symptoms 
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with the presence of arrhythmias or to confirm that arrhythmias are not 
present at the time of symptoms and therefore rule in or out a cardiac cause 
for a patient’s symptoms.  However, the bradycardia settings in the PULSE 
trial were the same as those suggested by the ISSUE investigators (69) and 
the research undertaken in this literature review suggests that it is our practice 
that needs reviewing.  One would also have to question the tachycardia and 
asystole settings from the PULSE study as even at the manual review stage, 
tachycardias above 150bpm and asystoles greater than two and a half 
seconds were passed to the physician for further assessment, a point that 
may have affected the outcome of the study.  Their extended manual criteria 
for supraventricular tachycardias (SVTs) of greater than 30 seconds, 
(accelerated) idioventricular rhythm greater than ten beats, ventricular 
tachycardia (VT) greater than four beats, ventricular fibrillation/flutter (VF), 
torsades de pointes and any second degree heart block with bradycardia or 
complete heart block/atrioventricular dissociation were clinically sound. 
 
The results of the study showed that 223,226 ECGs were recorded over a 
mean eight and a half month follow-up period, which equated to an average 
monthly auto-detection of 685 ECGs per patient.  However only 117 relevant 
ECGs were found out of the 223,226 that were recorded which leads on to the 
conclusion of the study.  The researchers concluded that remote monitoring of 
ILRs may create excessive burden but that a sensitive detection criteria was 
still preferable in order to reduce the chance of missing arrhythmias and that 
they found relevant ECGs for 50% of their study patients.  Unfortunately they 
did not state whether ‘relevant’ ECGs equated to a diagnosis.  Neither did 
they allude to what the breakdown of the recordings was so it may actually 
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have meant that a recording of sinus bradycardia at 39-40bpm was recorded 
nocturnally in an asymptomatic patient and in reality none of the patients 
received a diagnosis. 
 
2.9. Article Two - Effectiveness of remote monitoring in the 
management of syncope and palpitations 
Article two by Furukawa et al (44) reported the use of Reveal™ and 
Carelink™ for the clinical management and acceptance of patients with 
syncope and palpitations. 
 
This was a multi-centre, prospective, non-randomized study which recruited 
47 consecutive patients who were over 18 years of age that had suffered from 
two or more episodes of unexplained syncope or palpitations. 
 
Patients in this study all received a Reveal™ DX or XT ILR and a Carelink™ 
home monitoring system.  Participants were asked to transmit the data from 
their ILRs on a weekly basis and on the day of any symptoms which resulted 
in a manual recording.  This method, whilst possibly eliminating the device’s 
memory saturation and reducing the time to detection of an automated 
recording, has the potential to create excessive additional workload for 
physicians and physiologists.  Weekly downloads it might also be argued go 
against the current guidelines of the National Institute for Health and Clinical 
Excellence (NICE) (4), and the European Society of Cardiology (ESC) (5) 
which suggest that ILRs should only be implanted in patients that have 
infrequent symptoms (less frequently than fortnightly).  This may be a prudent 
point to keep in mind as we move through the review of this article. 
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The researchers evaluated their data against an established and well-
reviewed standard, developed by the International Study on Syncope of 
Uncertain Etiology (ISSUE) investigators (69).   
 
Unfortunately there was no control group for this study: in order to overcome 
the lack of a built-in study control the researchers used previously published 
data to draw comparisons against their data.  This promotes several issues; 
firstly the data may be out-of-date so comparisons are already slightly biased 
and secondly due to differences in measurements the comparisons that can 
be drawn and statistically tested may become limited.  It is important to 
mention that the reporters were also aware of this and made reference to this 
shortcoming in their limitations section.  Unfortunately they then tried to say 
that this would only affect the results on diagnostic yield and the study was 
aimed at effectiveness and acceptance.  This perhaps is mildly deceptive on 
the researchers’ behalf as they also used the published data to compare the 
time taken to reach a diagnosis which was one of their primary markers for 
effectiveness. 
 
The results of this study state that they received true relevant ECGs in a 
median of 11 days, this suggests that some of their patients may have only 
required extended external ECG monitoring with an event recorder or Holter 
monitor.  However later on in the report the researchers do state that a ‘True 
relevant ECG’ is not the same as a diagnosis and that they ‘estimate’ a 
reduction in time to diagnosis of 71 ± 17 days. 
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One of the significant findings of this study was the acceptance factor of the 
Reveal™ ILR in conjunction with Carelink™ as it suggests that remote 
monitoring of ILRs is well accepted and that 70% of the study patients actually 
felt safer with the addition of Carelink™.  To date there is no literature 
available via searches of PubMed or Medline relating to the psychological 
impact of ILRs, in terms of waiting for another symptom to occur so that the 
medical team can observe, and whilst it is outside of the remit of the Real 
Care study it is the author’s opinion that this is an area which warrants further 
qualitative investigation, even if it focuses solely on the patient perspective of 
ILRs with the addition of remote monitoring. 
 
The researchers of the effectiveness of remote monitoring in the management 
of syncope and palpitations paper (44) concluded that remote monitoring is a 
powerful additive tool to use in the unexplained syncope and palpitations ILR 
population.  Carelink™ is well accepted and weekly transmissions are optimal 
for the majority of patients.  From researching the previously reviewed papers 
(44,45) and from clinical experience the author suggests that weekly 
downloads may create an excessive burden on patients and clinical staff 
whilst potentially not offering a significant improvement in diagnostic 
capabilities of ILRs. 
 
2.10. Article Three - Effectiveness and safety of remote monitoring of 
patients with an implantable loop recorder 
The third and final paper (68) to be reviewed was perhaps the most robust 
and the only one to openly admit the presence of time and selection bias.  
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The reporters did try to play this down by saying that the baseline 
characteristics were similar and that their cohorts were implanted sequentially. 
 
The effectiveness and safety of remote monitoring of patients with an 
implantable loop recorder study was a single-centre historical cohort study 
comparing data collected from a group of ILR patients without Carelink™ 
(control) and a group of ILR patients with Carelink™.  The control group in this 
study had in-office follow-up with device interrogation and clinical assessment 
at three-monthly intervals while the Carelink™ group sent monthly 
transmissions or transmissions within 24 hours of a symptomatic episode.  
The Carelink cohort also had a two-way telephone contact service available in 
case of syncope or a significant event. 
 
Their study included all patients that had a Medtronic Reveal™ DX or XT 
between January 2003 and December 2010.  In total there were 109 patients 
in this study broken down to  1 in the control group and  8 in the Carelink™ 
group.  The control group patients received their devices between January 
2003 and October 2010 and the Carelink™ group were implanted between 
June 2009 and December 2010.   
 
The study analysed for the most part the same variables as the previous 
studies (age, gender, number of recordings, number and type of both true and 
false recordings, time from event to follow-up, and time to diagnosis) and also 
used the ISSUE (69) classification to categorise and determine whether an 
ECG was significant or not.  In addition to this they also looked at the type and 
frequency of visits that patients made to the hospital in order to see if remote 
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monitoring of ILRs affected hospital presentations and which mode of 
presentation has the most significant alteration.  Finally the researchers 
looked at the time not only to diagnosis but also to the time to initiation of 
treatment and the specific treatment prescribed in response to a significant 
ECG. 
 
This was the only study of the three to use statistical tests to measure the 
significance of their results; the researchers stated that they used the Mann-
Whitney U test for non-parametric results and the Pearson chi-squared test for 
frequency data.  However they also stated that the frequency data was 
qualitative not quantitative, therefore they would not have been able to use 
the Pearson chi-squared test unless their qualitative work was a hybrid of 
qualitative and quantitative research and used a Likert scale.  While the use of 
Likert scales is commonplace in research there are those hard-core qualitative 
researchers that would state that this is in fact quantitative in nature as it can 
be statistically analysed.  It is more likely however that this is due to a 
typographic error, a translational error as the original article was written in 
Spanish, or it could be a reflection of the peer review process. 
 
The researchers concluded that the use of remote monitoring enhanced the 
diagnostic ability of ILRs by reducing the time taken to encounter a significant 
event and also reach a diagnosis, therefore reducing the time taken to 
implement a specific treatment.  The researchers reported that the time taken 
from implant of the ILR to diagnosis of a significant event was 56 (0 - 650) 
days vs 260 (5 - 947) days p <0.01 and that the time device implant to 
initiating treatment was significantly different at 73 (0 - 650) days vs 260 (5 - 
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947) days for remote monitoring and conventional care respectively (p <0.01). 
The study also highlighted that the use of remote monitoring effectively 
reduced the number of planned and unplanned visits not only to cardiac 
diagnostic units but also to accident and emergency departments. 
 
2.11. Summary of the key evidence 
All of the studies made some valid points but none of them were without their 
flaws, primarily this was down to one or all of the following: 
 
1. Lack of a control groups - studies one and two 
 
2. Non-concurrent control group - study three 
 
3. None of the studies had any randomisation 
 
Coupled with the above problems was the inherent potential for bias to 
influence the interpretation of the studies.  On the whole the reporters were 
open about the limitations but in all cases attempts were made to either justify 
the areas liable to bias or play down the problems that could arise. 
 
All of the studies were in favour of the use of remote monitoring with ILRs but 
there is too much left to chance for certainty and a powered fully randomised 
and controlled study that minimises the possibility of bias and chance findings 
is the only way to be sure that remote monitoring does not become a service 
that is draining healthcare resource without improving the diagnostic services 
provided. 
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While there is a plethora of information and research surrounding the ILR 
itself, it appears from the literature that we as clinical healthcare professionals 
are either happy to accept the addition of new technology without robust 
research or that we are going the other way and refusing to accept that there 
may possibly be a better way to look after our ILR patient population. 
 
2.12. Summary of the chapter 
Syncope and palpitations are symptoms that can potentially have life 
threatening consequences and a negative impact on patient’s lives in terms of 
anxiety and lifestyle if undiagnosed.  Unfortunately diagnosis of the underlying 
cause can be prolonged simply by the test employed and the frequency of the 
symptoms.  The evidence presented in this chapter suggests that ILRs are a 
valuable and effective tool for either diagnosing a cardiac cause for symptoms 
or ruling out a cardiac cause for symptoms.  That same evidence suggests 
that whilst the ILR is an effective tool it can still be a lengthy pathway.  
However, ILRs in conjunction with remote monitoring has shown potential in 
reducing the diagnostic time for patients with syncope and palpitations, 
therefore ensuring that patients receive the correct treatment without delay.  
Whilst the evidence suggests a potential to reduce diagnostic time there is not 
enough data prove this. 
 
The literature review, particularly the three articles reviewed highlighted that a 
more robust study was required.  The REveAL™ and Carelink™ (Real Care) 
study was designed as the first prospective, randomised, clinician blinded, 
controlled trial in this field to address the lack of robust evidence relating to 
remote monitoring of ILRs.   
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Chapter 3.  Real Care study aims, objectives, design and implementation 
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In this chapter the aims, objectives and full methodology including the 
REveAL™ and CARElink™ (Real Care) study design are covered.  The 
protocol for the study can be found in Appendix 1. 
 
3.1. Aims of the Real Care study 
The primary aims of the Real Care study were to ascertain if: 
 
1. The average time to follow-up from a true event occurring can be 
reduced if remote monitoring is included in the patients care pathway. 
 
2. The average time taken to achieve a diagnosis in the implantable loop 
recorder (ILR) population could be reduced with the use remote 
monitoring equipment. 
 
The secondary aims for this study were to ascertain: 
 
1. How much data is generated for review (review burden) by true and 
false recordings, both with and without the use of remote monitoring? 
 
2. Does remote monitoring impact ILR memory saturation? 
 
3. Can age or gender be used as determinants to predict diagnosis? 
 
4. What CDDFT’s ILR diagnostic yield is. 
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5. What is the trigger for true and false ILR recordings in terms of 
arrhythmia, artefacts or signal sensing and how do they breakdown into 
diagnosis? 
 
6. How long does it take to record the first true event? 
 
7. What the primary implant indications are in CDDFT hospitals? 
 
8. What is the response to diagnosis (in terms of monitoring)? 
 
The secondary aims are split into sections; the first two of the secondary aims 
are assessing the impact of remote monitoring on clinical activity and device 
memory.  It was suggested by Arrocha and colleagues (45) that remote 
monitoring could create an excessive amount of data to be reviewed and by 
Furukawa and colleagues (44) that remote monitoring could almost eliminate 
ILR memory saturation therefore minimising potentially missed true events.   
 
The next section of the secondary aims (secondary aim 3) was aimed at 
discovering whether age or gender can be used as predictors of diagnosis, 
this would be of particular interest if remote monitoring proved to be superior 
in the primary aims but created excessive data and therefore needed a 
selection criterion.  For example, if patients in the 30-50 year old age group 
were more likely to receive a diagnosis then perhaps they should be targeted 
with home monitoring first. 
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The final section of the secondary aims (secondary aims 4 - 8) will assess the 
not only the diagnostic yield  but what the actual recordings were from the 
patients in the Real Care study in terms of arrhythmias, artefacts, and sensing 
issues such as signal dropout and how they breakdown into diagnosis?  
Moving on to assess whether CDDFT is implanting devices for appropriate 
reasons and what in terms of monitoring strategy (i.e. explant or continue to 
monitor) is the response to diagnosis.  Whilst this final section of the 
secondary aims could potentially be seen as audit data it is also important 
information when considering the effectiveness of remote monitoring as the 
results could be skewed if the implant data and diagnostic yield were 
inappropriate. 
 
3.2. Objectives of the Real Care study 
The primary aims were to be achieved by collecting the follow-up data of the 
control and experimental groups of ILR patients that participated in the Real 
Care study and statistically analysing the data to determine if there was a 
significant change in the time taken to reach a diagnosis, be it a cardiac or 
non-cardiac diagnosis. 
 
The secondary aims were to be achieved by collecting data and analysing the 
results using descriptive statistics, and comparing group data statistically 
where possible.  Cox regression will be used to see if age group, gender or 
study group used as determinants affected the hazard ratio (HR) of a 
diagnosis being reached with the use of an ILR. 
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3.3. Study design, setting the scene 
The Real Care study was a prospective, randomised, clinician-blinded study 
carried out within County Durham and Darlington NHS Foundation Trust 
(CDDFT), using consecutive and informed patients who received an 
implantable loop recorder (ILR).  The three main sites of the Trust in which 
research activities were carried out were the Cardiac and Respiratory 
Services Departments at Darlington Memorial Hospital (DMH), Bishop 
Auckland General Hospital (BAGH) and University Hospital of North Durham 
(UHND).  This included the two Cardiac Catheterisation Laboratories (Cath 
Labs) at DMH and UHND.  Data analysis was carried out on an intention-to-
treat basis; therefore all the results of the patients who completed the study 
were analysed in their respective group, regardless of crossover or non-
compliance. 
 
3.4. Research and study team structure 
Figure 11 shows the structure of the research team including those directly 
involved in the study and the supervisors.  The interaction points are also 
highlighted with arrows. 
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Figure 11 - Research / Study team stucture 
 
 
3.5. Ethical approval 
The Real Care study received favourable ethical opinions from the Northeast 
Regional NHS Ethics Committee and the Durham  niversity’s School of 
Medicine, Pharmacy and Health Ethics Committee. 
 
3.6. Trial registration 
The Real Care trial was registered with the International Standard 
Randomised Controlled Trial Registry and the International Standard 
Randomised Controlled Trial Registration Number (ISRCTN) is 
ISRCTN72340423. 
 
3.7. Training 
Before carrying out research or to be involved in research within the NHS in 
England, it is a requirement that researchers and members of staff 
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undertaking any research activities have completed the Introduction to Good 
Clinical Practice in Research (GCP) programme.  All members of the research 
team for the Real Care study completed this before commencing any research 
activity related to the study.  All members of the team also completed and 
passed the beINFOrMED online consent training and assessment programme 
and the participating physiologists all held or were working towards their 
British Heart Rhythm Society (BHRS) formerly Heart Rhythm UK (HRUK) 
accreditation in cardiac rhythm management (CRM) devices. 
 
The Chief Investigator (CI) and author also attended courses on quantitative 
research, qualitative research, basic statistics, logistic regression, syncope 
courses, and cardiac educational seminars and conferences (national, local 
and industry). 
 
3.8. Patient involvement 
The patient information sheet (PIS) (Appendix 2) was reviewed informally by 
patients attending the devices clinic and it was decided that a formal 
arrangement for patient involvement was required. 
 
A Patient Advisory Group (PAG) consisting of four patients was formed.  This 
group consisted of previous and current ILR patients both with and without 
Carelink™ e perience.  The PAG was asked to review any changes to the 
PIS and supporting information.  They were also asked if they would be willing 
to assist with any patient concerns that may have arisen.  The members of the 
PAG were chosen based on not only their expertise but also on the value it 
was felt that they could add to the study. 
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Letters were sent to the proposed members of the PAG asking them if they 
would be interested in assisting with the study.  If they were keen to take part 
they were asked to attend a meeting at their local CDDFT hospital where they 
were fully informed of the study and their role as a member of the PAG.  The 
meeting was hosted by the CI who also informed them that their involvement 
was entirely voluntary and that they were free to leave the group at any time. 
 
There was no provision for financial gain for PAG members but travelling 
expenses for PAG duties such as meetings were paid in line with current 
CDDFT allowances.  Additionally, refreshments were provided at meetings. 
 
Participants in the Real Care study were given the contact details of an 
independent person that was available to answer questions on research in 
general and mediate if the participant had any concerns that they did not wish 
to directly speak to a researcher about. 
 
3.9. Recruitment – Who and How? 
Historic implant and growth rates were used to predict that 95 ILRs would be 
implanted in the 2012/13 financial year with a further significant increase in 
the 2013/14 financial year.  Due to the previous implanting data and 
subsequent predictions, a recruitment period of 24 months was allowed for 
the Real Care study. 
 
In order to reduce patient selection bias that could be created by physiologists 
only choosing patients that they felt might have a positive outcome, all 
patients that received an ILR at one of the CDDFT Catheter Laboratories 
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were given a brief verbal description of the Real Care study and asked for 
verbal consent for a PIS being posted to their home address prior to their first 
follow-up. 
 
Following an amendment to the protocol which was approved by the ethical 
committees mentioned in section 3.4 the recruitment process was altered so 
that patients received a PIS prior to the day of implant.  This was given at the 
pre-assessment appointment allowing the patient time to read the information 
and have a minimum of a 48 hour cooling off period.  Patients were asked on 
the day of their implant if they would like to take part in the study.  If they 
agreed, the consent form (Appendix 3) was signed and the randomisation was 
carried out providing that the patient was eligible against the inclusion and 
exclusion criteria.  In some instances the patient asked for more time to 
consider their position, in these instances the patient was asked again at their 
first follow-up. 
 
Recruitment to the Real Care study was slower than originally anticipated, the 
problem with this was believed to be the protocol issue and would be resolved 
by the amendment made to the way in which patients received the PIS.  
Whilst the amendment did increase the recruitment rate, there were still a 
large number of patients not entering the study.   
 
In total 185 patients received a PIS, 148 (80%) of those were not included in 
the study.  Of that 148 patients, 28 (19%) patients did not meet the inclusion 
criteria (Section 3.10) (this included ten patients that received a different ILR 
device) and 31 (21%) declined to participate.  That left 89 patients which was 
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48% of the overall number of patients that received a PIS, not included in the 
study and 37 patients that entered randomisation.  The issues that impacted 
the recruitment rate are covered in more detail in the discussion in Chapter 7. 
 
The breakdown of the 37 patients randomised was, 19 to the control arm and 
18 to the experimental arm with one patient initially non-compliant and then 
lost to follow-up in the experimental arm.  A further two patients that, whilst 
they did comply with the use of the equipment in the experimental arm, they 
missed transmissions on a regular basis. 
 
Figure 12 shows a graph of the planned recruitment and the actual 
recruitment to the Real Care study over the 24 month recruitment period. 
 
Figure 12 - Graph showing actual and predicted patient recruitment to 
the Real Care Study 
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Analysis of the age and gender profile of the patients not included in the study 
showed no statistically significant differences when compared to those that 
were included in the Real Care study. 
 
3.10. Inclusion Criteria 
The inclusion criteria for patients implanted with a Medtronic ILR device at 
CDDFT hospitals were that they: 
 
1. Were aged 18 years or over 
 
2. Had access to a landline telephone 
 
3. Were themselves cognitively capable to consent 
 
4. Had the ability to use the manual activator and Carelink equipment or 
had a willing and appropriate adult to do so for them 
 
5. Were able to communicate and understand instructions given in English 
 
The reasoning behind the final point on the list is that due to this being a Trust 
or ‘in-house’ funded study the financial provision was not available to have 
translators available for fortnightly follow-up in the experimental patient group.  
Nor was it financially viable to have the literature published in multiple 
languages. 
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3.11. Exclusion Criteria 
Patients were excluded from the study if: 
 
1. They did not have access to a landline telephone 
 
2. They had documented cognitive impairment that meant that they were 
unable to consent 
 
3. Were unable to comply with the use of any equipment 
 
4. Patients that were considered for Carelink for geographical reasons e.g. 
living in the secluded villages within the CDDFT catchment 
 
5. They could not communicate or understand instructions given in English 
  
3.12. Sample size considerations 
The sample size required for this trial was calculated using data collected in 
an audit of CDDFT ILR patients on conventional follow-up, and a decision 
made by the research team, that in order to make a trust-wide remote 
monitoring service viable a reduction in diagnostic time of 50% was required.  
Data from a recent service evaluation suggested that a 50% reduction was a 
realistic possibility.  The service evaluation used the data from 16 patients put 
prospectively on to the remote monitoring system and compared it to 
retrospective audit data from ten years of previous ILR implants within CDDFT 
hospitals.  ILR patient files were excluded if they were incomplete, received a 
device other than a Medtronic™ ILR, or if they had no floppy disk containing 
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their ILR recordings and data present.  In total there were 112 files included in 
the retrospective data collection.  The audit and service evaluation were 
carried out in 2012 by Gareth Pounds (author of this thesis). 
 
Data from the retrospective audit indicated that 85% of patients on 
conventional (control) ILR follow-up had not received a diagnosis after 12 
months.  After clinical discussion it was adjudged that this could be reduced to 
 3% of the patients, using Carelink™ remote (e perimental) follow-up over 
the same time period.  Using the software program nQuery7 and a log rank 
sample calculation for proportional reduction a total of 52 patients were 
required to enter this study, 26 patients into the control arm and 26 patients 
into the Carelink™ arm.  The alpha (α) error was set to 0.0  and the beta (β) 
error was set to 0.1, giving a two tailed significance of 5% and a power of 90% 
[100(1 – β)], see Table 3 - nQuery7 output. 
 
Table 3 - nQuery7 output 
Two group 2 test of equal proportions (odds ratio = 1) (equal n's) 
Test significance level,    0.050 
1 or 2 sided test?    2 
Group 1 proportion, 1  0.850 
Group 2 proportion, 2  0.430 
Odds ratio, =2(1-1)/[1(1-2)]     0.133 
Power ( % )      90 
n per group  26 
 
 
As a precaution to allow for dropouts and loss to follow-up, an additional 10 
patients per group were added into the calculation.  This gave a total of 72 
patients in the study, 36 patients per group. 
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The sample size decisions were reviewed and approved by Dr Douglas 
Wilson, Statistician at Durham University, School of Medicine, Pharmacy and 
Health. 
 
3.13. Treatment arms 
The Real Care study consisted of two treatment arms, a control arm and an 
experimental arm.  Patients randomised to the control group were followed up 
in the conventional manner within CDDFT hospitals.  The patients were seen 
in the clinic five weeks post implant and then at six-monthly intervals or if they 
had suffered three symptomatic episodes or one episode that they were 
particularly concerned about.  At each follow-up for control group patients, the 
patient had their ILR interrogated and any stored ECGs were classified 
according to the Real Care classification table (Table 4) adapted from the 
table created by the International Study on Syncope of Uncertain Etiology 
(ISSUE) investigators (69) (Figure 13 - The ISSUE Classification table taken 
from Brignole et al 2005 .  This was the same process regardless of whether it 
was a standard six-month appointment or an additional appointment due to 
the patient having the symptoms associated with their implant, such as 
syncope, severe dizzy spells or palpitations.  All data was then stored 
electronically to ensure that classifications could be verified at a later date. 
 
The experimental arm patients received the same five week and six-monthly 
appointments as the control arm patients but in addition to this they received 
the Carelink™ remote monitoring equipment.  The equipment was 
demonstrated when it was issued and also had simple instructions supplied 
with it (Figure 10).  Patients were asked to send their data at fortnightly 
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intervals and send additional transmissions if they had a symptomatic 
episode.  Any ECGs which had been downloaded and transmitted were 
classified using the same criteria as the control patients.  All transmissions 
were stored on the Carelink™ network and were also stored as PDFs on the 
CDDFT servers in order to avoid data loss in the event of a network failure 
and to allow for later verification. 
 
3.14. Procedure for all follow-ups with significant ECGs 
If a patient presented to follow-up (in-office or remote) with a clinically 
significant ECG recording, the physiologist printed the recording, removed the 
identifiable data, and labelled the printout with the patient’s study number.  A 
cardiologist was then asked to review the recording along with symptom data.  
If the patient required any form of intervention as a direct result of the 
recording then this was considered to be a diagnosis and the patient was 
removed from the study. 
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Table 4 - The Real Care Classification of ILR ECG Recordings 
True Events False Events 
FVT or VT recording showing a 
tachycardia 120bpm, conclusively or 
believed to be a rhythm other than 
sinus tachycardia. 
 
Asystole recording showing an R-R 
pause of 3 seconds (for AF 3 
seconds diurnally and 4.5 seconds 
nocturnally) 
 
Bradycardia recording with a sudden 
decrease in heart rate of >30% or 
<40bpm for 10 seconds. 
 
Manual recordings displaying any of 
the above, or manual recordings 
showing no significant ECG changes 
/ false events but recorded in the 
presence of patient symptoms. 
 
FVT or VT recording showing sinus 
tachycardia or artefact. 
 
 
 
Asystole recording with evident 
under-sensing. 
 
 
 
Bradycardia recording with evident 
under-sensing. 
 
 
Manual recordings displaying any of 
the above, or no significant ECG 
changes if recording is made in the 
absence of symptoms or in the 
presence of symptoms not related to 
ILR implantation. 
 
 
Figure 13 - The ISSUE Classification table taken from Brignole et al 2005 
(69). 
 
(Permission requested from the ISSUE reporters) 
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3.15. Endpoints and outcomes 
The clinical endpoints of this study were: 
 
1. Time to diagnosis/outcome 
 
2. Device removal for any reason 
 
3. Death 
 
For an endpoint to be considered it had to occur within the 24 month follow-up 
period of the study.   
 
Primary outcomes were classed as positive, negative or none.  A positive 
outcome was for patients that receive a cardiac diagnosis, a negative 
outcome was for patients who could be confirmed not to have a cardiac cause 
for their symptoms and none was for the few patients who did not have a 
symptom or true event during the follow-up period. 
 
3.16. Randomisation 
Once patient consent and eligibility to join the trial were confirmed they were 
allocated a study number and randomised to either the control arm or 
Carelink™ (experimental) arm.  Randomisation was carried out in a block 
randomisation method using mixed blocks of four, six and eight on a 1:1 basis 
in order to maintain similar patient numbers in each group.  
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A randomisation table was generated by Dr Douglas Wilson, Statistician at the 
School of Medicine, Pharmacy and Health (SMPH) at the Durham University 
and held by an independent staff member within CDDFTs Clinical Innovation 
and Trials Unit (CITU).  Researchers contacted this team once a patient was 
enrolled.  The patient was then allocated a study number which was 
compared to the randomisation table by the independent staff and the patient 
was allocated to the control or experimental arm.  All correspondence was 
logged and researchers at no point had access to the randomisation table. 
 
The point of randomisation in the patient’s journey can be seen in Figure 14 - 
The Real Care patient care and data collection pathway on page 90 
 
3.17. Protocol amendment 
There was one amendment made to the Real Care protocol after the initial 
favourable ethical opinions were granted.  The amendment was related to 
recruitment and was considered to be minor changes which received 
continued ethical support.  More specifically the amendment altered the way 
in which patients received the PIS.  Originally patients received the PIS 
through the post after giving verbal consent to receive one on the day of 
implant.  The amended protocol meant that patients were given a PIS at their 
pre-operative assessment (two – seven days prior to implant) and were asked 
to consent on the day of ILR implant. 
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Chapter 4. Data collection, storage, verification, security and timelines 
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In this chapter the patient care and data collection pathway for the Reveal™ 
and Carelink™ (Real Care) study is presented.  The storage of data and the 
method of verification of data are described and the security of both 
identifiable and non-identifiable data will be explained. 
 
4.1. Patient care and data collection points for the Real Care study 
Figure 14 - The Real Care patient care and data collection pathway illustrates 
the patient care pathway followed during the study, including the data 
collection points and decision processes used. 
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Figure 14 - The Real Care patient care and data collection pathway 
 
ILR Implanted 
Patient Enrolled 
Randomisation 
Carelink  
demonstration given  
and kit ordered 
Control 
Carelink kit delivered  
to patients home  
address and test sent 
Yes 
Symptoms 
No 
Diagnosis Data  
Collection 
Yes No 
Six monthly follow up  
data collection 
Yes 
Symptoms 
No 
Diagnosis Data  
Collection 
Yes No 
Data Analysis 
Fortnightly + six 
monthly follow up 
Data collection 
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4.2. Data verification and storage 
All follow-up data from implantable loop recorders (ILRs) implanted into 
patients participating in the Real Care study was stored either to 3.5 inch 
floppy disk (control arm) or on Medtronic Inc.’s secure servers in The 
Netherlands (experimental arm) along with the follow-up forms filled in by the 
physiologist during the follow-up.  The use of 3.  inch floppy disks is an ‘old 
fashioned’ practice and one that is becoming increasingly difficult to use as 
local Information Governance (IG) policies demand more secure methods of 
data storage.  However, the Medtronic™ 20 0 model programmer will not 
accept secured or encrypted USB memory drives and these are the only other 
storage media currently available within the Trust (It is worth note at this point 
that Medtronic Inc. are currently working on a new generation of programmer 
which will be able to connect to the hospital WiFi, allowing data transfer 
directly to a sever within the trust or to the Carelink™ network).  The raw data 
stored on the floppy disks is encrypted and can only be read by a Medtronic™ 
programmer. As data was transferred to the data collection spreadsheet the 
chief investigator (CI) checked all ECGs from all follow-ups and verified the 
report made.  If the CI was the initial reporter then the ECGs were verified by 
another physiologist (Ruth Laity, Paul Skinner or Jane Curry) thus ensuring 
that all ECGs were verified.  If there were any discrepancies or disagreement 
on ECG classification then the ECGs were reviewed by another physiologist 
and the majority consensus was used.  There were only nine events during 
the entire study that required discussion but due to the nature of the potential 
discrepancy, the discussion was carried out during the follow-up as it could 
have altered the action taken at that time.  For example signal dropout can on 
occasion look like asystole and vice versa. 
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4.3. Data security and anonymisation for the Real Care study 
All relevant data were transferred from the patient’s medical notes and the 
departmental loop recorder file on to an analysis spreadsheet (spreadsheet 
A).  This spreadsheet held only non-identifiable patient data.  During the 
collection process the patient’s study number was used to link the patient to 
the spreadsheet. A second spreadsheet (spreadsheet B) containing all patient 
identifiable data used in the study (name, date of birth and hospital number) 
was also created.  Once the study was complete spreadsheet B containing 
the patient identifiable data was destroyed and patient study numbers were 
removed from spreadsheet A containing the analysis data.  Patients who 
requested copies of the findings of the study had their contact details retained 
until they received their copies of the appropriate study reports. 
 
All spreadsheets were created and managed by the Chief Investigator (CI) 
who also had overall responsibility for ensuring patient data was handled 
appropriately and that only anonymised data were presented or disclosed to 
those outside of the research team and the direct care group.  The Clinical 
Innovation and Trials Unit (CITU) within the Trust held the randomisation 
tables with patient initials and date of birth. 
 
4.4. Data and Data Protection 
During the trial patient identifiable data was available to the CI and clinical 
staff directly involved in the patients care only.  Once data had been 
anonymised it was available to the CI and the study’s supervisors.  All patient 
information was accessed and handled in a confidential manner throughout 
and any hard copies of data were stored in locked filing cabinets in locked 
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departments at one of the research sites.  All electronic information that 
contained patient identifiable information (PII) was stored on password 
protected networked CDDFT PCs, CDDFT encrypted laptops or Medtronic’s 
secure server.  Anonymous data was stored on password protected 
networked CDDFT PCs, CDDFT encrypted laptops or CDDFT encrypted USB 
memory sticks. 
 
Patient data were kept secure at all times in accordance with the Data 
Protection Act and local / national NHS information governance criteria. 
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Chapter 5. Statistical methodology 
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In this chapter the types of data that were collected during the Reveal™ and 
Carelink™ (Real Care) study and the statistical methods used to analyse the 
primary and secondary outcomes are presented. 
 
5.1. Data types in the Real Care Study 
The majority of data collected during the Real Care study was continuous 
data as it related to the time to an event occurring and the number of ECG 
recordings made, both manual and automatic.  The number of ECG 
recordings was recorded as both the total number and in the separate 
categories that the implantable loop recorder (ILR) distinguished, i.e: fast 
ventricular tachycardia (FVT), ventricular tachycardia (VT), bradycardia 
(Brady), and asystole (ASY).  These numbers were then further stratified as 
true and false. 
 
5.2. Statistical software 
All statistical analysis for the Real Care study was carried out using the 
Statistical Package for the Social Sciences (SPSS) version 20.  This was 
accessed using the County Durham and Darlington NHS Foundation Trust’s 
(CDDFT’s) and Durham  niversity’s licences.   
 
5.3. Statistical analysis, exploring the data 
All data was explored and assessed using descriptive statistics and plots 
where appropriate in order to gain an in-depth understanding of the data 
before hypothesis testing and further testing was carried out.  The reason for 
exploring the data in this way was to highlight anomalies and outliers, and to 
allow some visualisation of the data prior to analysis. 
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5.4. Statistical analysis, testing the primary outcome 
The primary outcome measures were related to the time to diagnosis and the 
time from ECG / event occurrence to follow-up.  More specifically, whether a 
cardiac or non-cardiac diagnosis could be made with a clinically significant 
reduction in time and whether significant ECG recordings could be followed 
up more quickly.  Due to the distribution of the data from pilot and published 
studies (44,68) the sample size was calculated to be analysed using the log 
rank (Kaplan – Meier) test for survival.   
 
The log rank test is commonly used when analysing the ‘survival’ and hazard 
ratio of data from this type of intervention comparison clinical trial (70).  Most 
commonly the test is used to try to prove an increase in actual survival or 
prevention of re-hospitalisation.  In this case however survival time is 
preferable when shorter as this would indicate that either a true event (Table 4 
- The Real Care Classification of ILR ECG Recordings) has been identified or 
that a diagnosis has been reached.  As with all tests, there are those that 
criticise its use, stating that the assumptions that all patients are equal at 
baseline in terms of health status and any other underlying reason that may 
cause an event to occur.  In most cases however, particularly in medical 
research these assumptions and possible shortfalls are acceptable as they 
are unavoidable and by using a randomisation technique the impact of any 
single interaction is reduced (71). 
 
5.5. Statistical analysis, testing the secondary outcomes 
The secondary aims of the Real Care study were to provide information on 
data review burden of conventional verses remote follow-up, impact of remote 
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monitoring on device memory saturation, whether age and gender can be 
used as determinants for diagnosis in the CDDFT ILR population; and to 
provide information regarding CDDFTs ILR implant rates, diagnostic yield and 
diagnosis, true and false event triggers, time to first event, implant indications, 
and response to diagnosis in terms of monitoring strategy. The secondary 
outcomes were to be calculated and presented using descriptive statistics and 
compared using statistical testing such as Mann-Whitney U where possible.  
Cox regression was to be used to see if age and / or gender could be used as 
determinants that affected the hazard ratio (HR) of a diagnosis being reached. 
 
5.6. Verification of statistical tests 
All tests and data were reviewed by the Chief Investigator (CI) and Statistician 
Dr Douglas Wilson (School of Medicine, Pharmacy and Health, Durham 
University) to ensure that the appropriate tests were used to analyse the data. 
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Chapter 6. Results 
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In this chapter the results of the Reveal™ and Carelink™ (Real Care) study 
are presented.  The chapter starts with a results analysis workflow diagram 
(section 6.1) and then goes into the analysis and results.  Before the analysis 
begins there is a brief recap of patient numbers in the form of a CONsolidated 
Standards Of Reporting Trials (CONSORT) Diagram.  In brief the order of the 
analysis is; demographic and descriptive statistics, followed by the primary 
and secondary outcome data. 
  
In basic terms the primary outcome analysis aimed to see if: 
 
a) True event ECGs could be picked up more quickly 
 
b) A diagnosis could be reached more quickly 
 
It is important to clarify that there is a difference between a true event ECG 
and a diagnosis.  True events are classified in Table 4 - The Real Care 
Classification of ILR ECG Recordings on page 85.   A single true event may 
be classed as not being clinically significant in some cases.  However, a 
diagnosis means that a cardiac cause for the patient’s symptoms can be ruled 
in or ruled out.  The term diagnosis is therefore used throughout this thesis 
with the terms ‘cardiac’ or ‘non-cardiac’.  
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6.1. Results analysis workflow 
 
 
CONsolidated Standards Of 
Reporting Trials 
(CONSORT) Diagram.   
Pg 101 
Descriptive analysis and 
exploration of the study 
participants at study level.  
Pg 103 
Descriptive analysis and 
exploration of the study 
participants at group level.  
Pg 103 
Comparison of age profile 
across study groups  
Pg 104 
Primary outcomes analysis 
Primary outcome analysis - 
Analysis of time from first 
true event to follow-up 
Pg 109 
Primary outcome analysis - 
Analysis of time to 
diagnosis 
Pg 114 
Secondary outcome 
analysis 
Real Care data review 
burden 
Pg 115 
Real Care device memory 
saturation analysis 
Pg 117 
Age and gender as 
determinants of diagnosis 
analysis 
Pg 118 
County Durham and 
Darlington NHS Foundation 
Trust's (CDDFT's) 
diagnostic yield 
Pg 120 
Analysis of true and false 
event triggers 
Pg 124 
Descriptive analysis of time 
to first true event 
Pg 127 
Primary implant indication 
analysis 
Pg 128 
Response to diagnosis 
Pg 129 
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6.2. CONsolidated Standards Of Reporting Trials (CONSORT) diagram 
for the Real Care study 
The CONSORT diagram was created by the CONSORT group to be used 
alongside the CONSORT statement.  The CONSORT group is made up of 
experts in clinical trial methodology and guideline development as well as 
journal editors and research funders.  CONSORT was designed to promote 
transparent and structured reporting of randomised controlled trials (RCTs) 
(72).  The statement was created with RCT reporting in terms of journal 
articles or funder reports in mind,  whilst the statement is helpful and the 
points are covered within this thesis the suggested structure does not quite fit 
and therefore only the diagram was used.   
 
The reason for using the diagram is to provide a quick overview of how many 
patients were assessed, enrolled, excluded, randomised, allocated to each 
group, lost to follow-up, and finally analysed.  The CONSORT diagram can be 
found in Figure 15. 
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Figure 15 - CONSORT diagram 
 
 
Assessed for eligibility 
at the completion of 
study (n=185) 
Excluded  (n=148) 
   Not meeting inclusion 
criteria (n=28) 
   Declined to participate 
(n=31) 
   Other reasons (n=89) 
Analysed  (n=19) 
 Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Allocated to control arm (n=19) 
Lost to follow-up (initially non-
compliant then moved out of area) 
(n=1) 
Allocated to experimental arm 
(n=18) 
 Received allocated intervention 
(n=18) 
 
Analysed  (n=18) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomised 
(n=37) 
Enrolment 
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6.3. Descriptive analysis and exploration of the study participants 
6.3.1. Descriptive analysis and exploration of the study participants at 
study level 
Of the 37 patients available for analysis there were 19 male and 18 female.  
The mean age of the combined groups was 63 ± 16 years with a median age 
of 63 (36 – 89) years.  Table 5 - Descriptive statistics for participant gender 
and age shows the age and gender profile of all participants in the Real Care 
study. 
 
Table 5 - Descriptive statistics for participant gender and age 
 No. of 
Patients 
% 
of 
total 
Mean 
Age 
(Years) 
Std. 
Deviation 
Median 
Age 
(Years) 
Minimum 
Age 
(Years) 
Maximum 
Age 
(Years) 
Total 37 100 63 16 63 36 89 
Female 18 49 63 15 67 36 88 
Male 19 51 62 17 60 36 89 
 
The mean age breakdown for gender was 63 ± 15 years and 62 ± 17 years for 
female and male respectively.  The median age breakdown by gender was 67 
(36 - 88) years for female participants and 60 (36 - 89) years for male 
participants.  
 
6.3.2. Descriptive analysis and exploration of the study participants at 
group level 
The 18 patients in the e perimental (Carelink™) arm were made up of ten 
males and eight females.  The mean age of the group was 59 ± 15 years with 
the female / male breakdown being 57 ± 13 years / 62 ± 18 years respectively.  
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The median age for the group was 58 (36 – 84) years, female 66 (37 – 86) 
years, male 68 (36 – 89) years (Table 6). 
 
The 19 patients in the control (conventional care) arm were made up of 11 
males and eight females.  The mean age of the group was 65 ± 16 years with 
the female / male breakdown being 70 ± 14 years / 63 ± 17 years respectively. 
The median age for the group was 60 (36 – 86) years, female 74 (45 – 88) 
years, male 68 (36 – 89) years (Table 6). 
 
Table 6 - Descriptive statistics for age and gender breakdown for Real Care 
participants by study group shows the age and gender breakdown for Real 
Care participants when stratified by study group.   
 
Table 6 - Descriptive statistics for age and gender breakdown for Real 
Care participants by study group 
Study 
Group 
  No. of 
Patients 
Mean 
Age 
(Years) 
Std. 
Deviation 
Median 
Age 
(Years) 
Min 
Age 
(Years) 
Max 
Age 
(Years) 
Exp          
 
Female 10 57 13 59 36 84 
Male 8 62 18 66 37 86 
Group Total 18 59 15 60 36 86 
Con           
 
Female 8 70 14 74 45 88 
Male 11 63 17 68 36 89 
Group Total 19 66 16 69 36 89 
 
6.3.3. Comparison of age profile across study groups 
The Mann-Whitney U test carried out on distribution of age showed that there 
was no significant difference in the age profiles across the two study groups.  
The output showing the tests carried out by SPSS as part of the Mann-
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Whitney U comparison can be seen in Figure 16 - Mann-Whitney U test 
comparing age distribution across the study groups.   
 
Figure 16 - Mann-Whitney U test comparing age distribution across the 
study groups 
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6.4. Primary outcome analysis 
The time taken to reach a diagnosis for ILR patients can be prolonged due to 
a variety of reasons already covered in this thesis.  Essentially the Real Care 
study was designed to determine whether the use of remote monitoring in 
conjunction with ILRs is a practical means of reducing the time taken to 
achieve a diagnosis, or reducing the time taken to discover potentially 
diagnostic ECG recordings.   
 
In short, statistically the answer to both of these questions is yes.  The results 
of the statistical tests carried out for the analysis that derived the answer to 
the basic questions are presented in this section. 
 
In order to assess the differences in time from true event ECG to follow-up, 
the Mann-Whitney U test was used initially to confirm a significant difference, 
advanced analysis was then carried out using survival testing.  Survival 
testing commonly referred to as time to event (TTE) testing can be defined as 
a method group for analysing data where the desired outcome is time to 
occurrence of an event e.g. time to discovery / follow-up of a true event ECG, 
or time to diagnosis.  The time to a defined binary event or survival time can 
be measured in days, weeks, years, etc from an unambiguous onset of a 
specific follow-up period (e.g. date of randomisation) until its end e.g. 2 years. 
There are some important features of TTE analysis some of which are right-
censored in nature (the true unobserved event is to the right of the censoring 
time); i.e., all that is known is that the event has not happened during follow-
up and not that an event will not occur.  In simple terms the right censoring 
occurs when the event of interest did not occur in the follow-up period, or if 
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the participant left the study before the event had occurred.  The censoring 
time is the time at which either the patient left the study or the study ended 
without the event of interest occurring.  This often happens when a study uses 
staggered entry (as in the Real Care study) - ‘patients’ do not all enter the 
study at the same time; patients may not have experienced the event at the 
time  when the study ends (right-censored at study termination); or else 
patients have dropped out (right-censored at drop-out) and the last time they 
were monitored the event had not occurred; some patients become  lost in the 
middle of the study (right censored-lost to follow-up), and the last time they 
were monitored they were event-free. In the case of right-censoring where the 
study is designed to end after a pre-set time but patients do not have the 
same censoring time, this is referred to as ‘random type 1 right-censoring’ 
which is the most common form of right censoring. If there was no censoring, 
and subject to appropriate transformation of the time to event, linear 
regression analysis could be used. However, TTE analysis is more 
appropriate because time to event has a skewed distribution; the probability of 
being event-free past a certain time point may be of more interest than the 
expected time of event; and the hazard function used in TTE can lead to 
greater insight into significant failure factors that may be of clinical interest.   
 
For analysis of the Real Care data Kaplan-Meier was the advanced analysis 
tool used within the Statistical Package for the Social Sciences (SPSS) as it 
uses exact times events occur rather than the interval times used in other 
forms of survival analysis.  The use of exact event times over interval times 
makes Kaplan-Meier analysis more appropriate for this trial data and a 
significant advantage since the cumulative probability of having an event is for 
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that time point which takes on the value of the previous time point: 
consequently the TTE graph takes the form of a step function (and it is 
incorrect to join points other than by slopes of zero), a drop in value occurring 
only when an event occurs. It uses all available information and is useful for 
trial data of small sample sizes: censored times can be annotated on each 
event-free graph. For each time interval, t, the survival probability is calculated 
as the number of subjects surviving (number of patients living at the start of 
the time (e.g. 2 months minus the number of events) divided by the number of 
patients at risk (all living at the start) and those who are censored are not 
included in the denominator. Total probability of event-free occurrence up to 
that time interval is  obtained by  multiplying all the probabilities of being 
syncope-free at all time intervals preceding that time (i.e. by applying law of 
multiplication of probability to calculate cumulative probability). For example, 
the probability of patients being syncope-free three months after 
randomisation can be considered to be the probability of being syncope-free 
after two months multiplied by the probability of being syncope-free in the third 
month. This second probability is called a conditional probability. Although the 
probability calculated at any given time interval (i.e. every three months) is not 
very accurate because of the small number of events, the overall probability of 
being event-free at each specific time point is more accurate. 
 
Formally, the Kaplan-Meier estimate of remaining event-free is given by 
k patients having events in the period of follow-up at distinct 
times t1<t2<t3<t4<t5<⋯<tk. The probability of being event-free at time tj, S(tj), is 
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calculated from S(tj−1) the probability of being alive at tj−1, nj is the number of 
patients alive just before tj, and dj the number of events at tj, by 
 
 
 
Furthermore SPSS uses the Log-rank test as part of the Kaplan-Meier 
analysis to compare event free probabilities and demonstrate the significance 
of any observed changes between groups. 
 
6.4.1. Analysis of time from true event to follow-up 
Moving on to the first set of primary outcome data, the median time from first 
true event ECG to follow-up in the combined group data was 2 (0 – 24) 
weeks.  The median time from first true event ECG to follow-up in the 
experimental group data was one (zero – five) week and the median time from 
first true event ECG to follow-up in the control group was three (zero – 24) 
weeks.  The median, minimum, and maximum figures can be seen in Table 7 
- Descriptive statistics for Real Care time from true event to follow-up, 
complete and split by group. 
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Table 7 - Descriptive statistics for Real Care time from true event to 
follow-up, complete and split by group 
   
Combined                          N= 
Median (Weeks) 
Minimum (Weeks) 
Maximum (Weeks) 
28 
2 
0 
24 
Exp                                    N= 
Median (Weeks) 
Minimum (Weeks) 
Maximum (Weeks) 
13 
1 
0 
5 
Con                                   N= 
Median (Weeks) 
Minimum (Weeks) 
Maximum (Weeks) 
15 
3 
0 
24 
 
 
The Mann-Whitney U test outputs (Figure 17 and Figure 18) highlight that 
there was a statistically significant difference between the median times for a 
true event to be discovered at a follow-up between groups. 
 
Figure 17 - Test of median time from true event to follow-up 
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Figure 18 - Mann-Whitney U test comparison illustration and test  
statistics used in the calculation 
 
 
The analysis results seen in Table 8 - Median survival for time from a true 
event to follow-up shows that 50% of patients that have a true event ECG in 
the control group will have had to wait an estimated three weeks until they 
were followed-up, whereas 50% of the patients in the experimental group are 
estimated to have had their follow-up one week after a true event occurred.   
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Table 8 - Median survival for time from a true event to follow-up 
Study 
Group 
 Median (Weeks) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
 Exp 
Con 
Overall 
1.000 .585 .000 2.674 
3.000 1.449 1.790 4.210 
2.000 .754 .577 3.423 
 
The survival plot in Figure 19 - Survival plot for time from true event to follow-
up shows that the survival probability of experimental group patients having to 
wait for their true event to be followed-up is lower at all time points.  It is 
worthwhile noting at this point that “survival” is not the primary outcome of this 
study and that the endpoints depicted in the survival plots are those of true 
event occurrence and diagnosis. 
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Figure 19 - Survival plot for time from true event to follow-up 
 
 
 
The log-rank test showed that there is a statistically significant difference (p = 
0.004) between the time taken from a true event occurring and the 
subsequent follow-up depending on the mode of follow-up.  The results of the 
log-rank test can be seen in Table 9 - Log-rank test results for time from true 
event ECG to follow-up 
 
Table 9 - Log-rank test results for time from true event ECG to follow-up 
 Chi - 
Square 
df Sig. 
Log Rank (Mantel – Cox) 8.105 1 .004 
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6.4.2. Analysis of time to diagnosis 
The primary outcome of diagnostic time difference is shown in the survival 
plot, and the log rank test table in Figure 20, Table 10 and Table 11. 
 
Table 10 - Median time to diagnosis by study group 
Study 
Group 
Median (Weeks) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
  Exp 
Con 
Overall 
6.000 2.372 1.351 10.649 
13.140 3.853 5.589 20.691 
10.000 .799 8.435 11.565 
 
Figure 20 - Survival plot for time to diagnosis by study group 
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Table 11 - Log-Rank test results for time to diagnosis by study group 
 Chi - 
Square 
df Sig. 
Log Rank (Mantel – Cox) 3.889 1 .049 
 
Figure 20 - Survival plot for time to diagnosis by study group shows an early 
divergence in time to diagnosis between the two groups, with the 
experimental group clearly receiving a diagnosis more quickly.  However this 
is only of borderline statistical significance as demonstrated by the Log-Rank 
test with P = 0.49.  Further discussion of this and the relationship between 
statistically significant and clinically significant findings is covered in Chapter 
7. 
 
6.5. Secondary outcome analysis 
6.5.1. Real Care data review burden 
In total the Real Care study produced data from 5526 event recordings (total 
of automated and manual recordings, with and without ECG) for review in the 
analysis.  It is worth mentioning again at this point that the Reveal™ ILR can 
only hold 49.5 minutes of recording at any one time, if the memory is full then 
the oldest recording will be overwritten and the details of the event held as a 
text event.  The text includes time and date of event, duration of event, heart 
rate (min, max, and average) along with the device classification of the event.  
Whilst not as informative or potentially diagnostic as the ECG recordings, text 
events still require review particularly in patients with symptoms 
corresponding to the time of an event without ECG.  Text events are also 
important when looking at the duration of an arrhythmia, for example if a 
tachycardia rate is only just at the detection rate programmed in the ILR or 
  
116 
 
dips out of the detection zone slightly then enters the detection zone again, 
the device would record each dip as a separate event.  This would show as 
lots of recordings over the same time period when in fact it was a single 
sustained episode lasting from the first text recording to the last recording with 
ECG.  The 5526 events equated to 1711 ECG recordings requiring review 
and 3815 text events (without ECG) recordings.  (Recordings with ECG are 
between one minute and seven and a half minutes in length depending on 
whether the recording is automated or manual).  When breaking down the 
5526 event recordings into recordings per study group there were 1264 
events logged for the control group, 481 with ECGs and 783 without ECG to 
review and 4262 events logged for the experimental group, 1230 with ECGs 
and 3032 without ECG to review. 
 
On further investigating the 5526 events recorded.  The breakdown of these 
events was as follows.  In the experimental group 4262 recordings were 
logged, 1230 of those recordings had ECGs to analyse.  The breakdown of 
the recordings was 200 FVTs, 132 VTs, 216 asystoles, 2799 bradycardias, 
836 AT/AF, and 79 manual recordings.  Of the 1230 ECG recordings, 153 
(12%) were true events for this cohort.  There were 1264 recordings logged in 
the control group data with 481 ECGs to analyse.  The breakdown of this was 
206 FVTs, 22 VTs, 74 asystoles, 285 bradycardias, 527 AT/AF, and 150 
manual recordings.  Of the 481 ECG recordings, 122 (25%) were true events 
for this cohort. 
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6.5.2. Real Care device memory saturation analysis 
The mean device memory saturation was 18% and 25% for the experimental 
and control groups respectively.  There was no significant difference in the 
percentage of device memory saturation, regardless of whether follow-up 
mode was remote or conventional.  The results can be seen in Table 12 - 
Descriptive statistics for device memory saturation and Figure 21 - Device 
memory saturation Mann -Whitney U test results. 
 
Table 12 - Descriptive statistics for device memory saturation 
Saturation %   
Exp                                    N= 
Mean 
Std. Deviation 
Minimum 
17 
18 
30 
0 
Maximum 99 
Con                                   N=                                    
Mean 
Std. Deviation 
Minimum 
19
25 
35 
0 
Maximum 95 
 
Figure 21 - Device memory saturation Mann -Whitney U test results 
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6.5.3. Age and gender as determinants of diagnosis analysis 
When performing Cox regression on the data from the Real Care study, using 
the variables, study group, age group in years (30-50, 51-70, 71 and over), 
and gender the test showed that when controlling for age group and gender 
the “risk” of diagnosis in the e perimental group was 2.  times higher than 
that of patients in the control group (HR = 2.709, p = 0.049).  Neither of the 
other variables (age and gender) were statistically significant.  It is worth 
noting however that if the age group variable was introduced as a categorical 
variable the hazard ratio (HR) was increased.  By introducing the variable this 
way, rather than controlling for just the average of each age group it also 
compares each age group against a ‘baseline group’ in this case the 30 – 50 
year old group.  The increase suggests that patients in the experimental group 
have a “risk” or chance just over three times that of the control patients of 
receiving a diagnosis (HR = 3.128, p = 0.028).  Table 13 and Table 14 show 
the results of the regression analysis. Unfortunately, the study was not 
powered to assess HR and with larger group sizes the effect of the variables 
included could be altered.  Therefore these results may require caution in their 
interpretation and transference as the possibility of a chance finding cannot be 
overlooked. 
 
Table 13 - Cox regression for study group, age group, and gender 
 
Variable B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
StudyGroup .997 .497 4.027 1 .045 2.709 1.023 7.172 
AgeGroup2 -.169 .293 .335 1 .563 .844 .476 1.498 
Gender .615 .445 1.909 1 .167 1.850 .773 4.428 
(AgeGroup2 (years) 30-50, 51-70, 71 and over.  N.B.SPSS uses group means in calculations) 
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Table 14 - Cox regression for study group, age group, and gender with 
age group as a categorical covariate 
 
Variable B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
StudyGroup 1.140 .518 4.840 1 .028 3.128 1.133 8.638 
AgeGroup2 
  
1.786 2 .409 
   
AgeGroup2(1) .411 .567 .526 1 .468 1.509 .497 4.584 
AgeGroup2(2) -.375 .646 .337 1 .561 .687 .194 2.436 
Gender .810 .483 2.806 1 .094 2.248 .871 5.797 
(AgeGroup2 = 30-50 years, AgeGroup2(1) = 51-70 years, AgeGroup2(2) = 71 and over) 
 
The original age groups were not suitable for the Cox regression analysis and 
therefore required updating.  This update reduced the data from five age 
categories down to three age categories (the original age grouping was 30-40, 
41-50, 51-60, 61-70, and 71 and over).  The rationale behind this update was 
to increase the numbers within the outlying categories and minimise the skew 
effect and interaction that occurred in the first Cox regression analysis 
attempt.  Table 15 and Table 16 show the initial Cox regression findings.  The 
influence of having five age categories, some of which had only four patients 
and were 75% male is clearly seen in Table 16. 
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Table 15 - Cox regression for study group and age group (Initial age 
group categories) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
StudyGroup .621 .297 4.363 1 .037 1.861 1.039 3.334 
AgeGroup   1.671 4 .796    
AgeGroup(1) .850 1.162 .536 1 .464 2.340 .240 22.800 
AgeGroup(2) .466 .683 .466 1 .495 1.594 .418 6.082 
AgeGroup(3) .476 .647 .541 1 .462 1.609 .453 5.721 
AgeGroup(4) .931 .774 1.448 1 .229 2.538 .557 11.567 
(AgeGroup = 30-40, AgeGroup(1) = 41-50, AgeGroup(2) = 51-60, AgeGroup(3) = 61-70, AgeGroup(4) = 
71 and over) 
 
Table 16 - Cox regression analysis on study group, age group and 
gender (Initial age group categories) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
StudyGroup .652 .299 4.742 1 .029 1.918 1.067 3.448 
AgeGroup   3.395 4 .494    
AgeGroup(1) 1.484 1.246 1.417 1 .234 4.410 .383 50.750 
AgeGroup(2) .204 .675 .091 1 .763 1.226 .327 4.600 
AgeGroup(3) .601 .658 .835 1 .361 1.825 .502 6.626 
AgeGroup(4) 1.214 .768 2.500 1 .114 3.367 .748 15.164 
Gender .502 .256 3.843 1 .050 1.652 1.000 2.729 
(AgeGroup = 30-40, AgeGroup(1) = 41-50, AgeGroup(2) = 51-60, AgeGroup(3) = 61-70, AgeGroup(4) = 
71 and over) 
 
6.5.4. County Durham and Darlington NHS Foundation Trust’s 
(CDDFT’s) diagnostic yield 
On analysis 28 (76%) of the 37 patients had a true event as classified in Table 
4 - The Real Care Classification of ILR ECG Recordings on page 85.  Table 
17 shows the frequency and percentages of participants that recorded a true 
event ECG. 
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As previously mentioned in the introduction to this chapter (page 99), there is 
a difference between a true event ECG and a diagnosis.  True events are 
classified in Table 4 - The Real Care Classification of ILR ECG Recordings on 
page 85.   A single true event may be classed as not being clinically 
significant in some cases.  However, a diagnosis means that a cardiac cause 
for the patient’s symptoms can be ruled in or ruled out.  However, as true 
events lead to diagnosis the analysis of them is included in the diagnostic 
yield section. 
 
Table 17 - Descriptive statistics for Real Care true event ECG 
frequencies 
True Event No. of 
Patients 
% of Total 
Yes 28 76 
No 9 24 
Total 37 100 
 
In Total 23 (62%) of the 37 patients received a diagnosis, and of those that 
received a diagnosis 15 (65%) received a cardiac diagnosis.  Table 18 - 
Descriptive statistics for Real Care diagnosis breakdown shows the frequency 
and percentages of participants in the Real Care data that received a 
diagnosis.  The diagnosis is then broken down further into cardiac and non-
cardiac where ‘Yes’ = cardiac diagnosis and ‘No’ = non-cardiac diagnosis in 
Table 19 - Descriptive statistics showing the breakdown of diagnosis into 
cardiac diagnosis. 
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Table 18 - Descriptive statistics for Real Care diagnosis breakdown 
Diagnosis No. of 
Patients 
% of Total 
Yes 23 62 
No 14 38 
Total 37 100 
 
Table 19 - Descriptive statistics showing the breakdown of diagnosis 
into cardiac diagnosis 
  No. of 
Patients 
% of Total Valid % 
Cardiac Diagnosis       Yes 
No 
Total 
15 41 65 
8 22 34 
23 62 100 
No Diagnosis 14 38 - 
Total 37 100 - 
 
When broken down into study group the data showed that 13 (72%) of the 18 
patients in the experimental group had a true event (Table 20) and that 10 
(56%) received a diagnosis (Table 21).  The data for the control group 
showed that 15 (79%) of the 19 patients had a true event (Table 20) and 13 
( 8%) of the group’s patients received a diagnosis (Table 21).  The SPSS 
outputs of event and diagnosis breakdowns are shown in Table 20 - 
Breakdown of true event frequencies split by study group and Table 21 - 
Breakdown of diagnosis frequencies split by study group.  In addition to the 
patients receiving a diagnosis one further patient reached a study endpoint 
due to device removal.  The device was removed at the patients request due 
to pain at the implant site. 
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Table 20 - Breakdown of true event frequencies split by study group 
   No. of 
Patients 
% of 
Total 
Experimental Group                 True Event                Yes 
No 
Total 
13 72 
5 27 
18 100 
Control Group                          True Event                Yes 
No 
Total 
15 79 
4 21 
19 100 
 
Table 21 - Breakdown of diagnosis frequencies split by study group 
  Diagnosis No. of Patients % of 
Total 
Experimental Group                                Yes 
No 
Total 
10 56 
8 44 
18 100 
Control Group                                         Yes 
No 
Total 
13 68 
6 32 
19 100 
 
Table 22 - Cardiac diagnosis breakdown, split by study group shows that of 
the ten patients in the experimental group that received a diagnosis, six (60%) 
received a cardiac diagnosis and four (40%) received a non-cardiac 
diagnosis.  In the control group data, of the 13 patients that received a 
diagnosis, nine (69%) received a cardiac diagnosis and four (31%) received a 
non-cardiac diagnosis.   
 
Table 22 - Cardiac diagnosis breakdown, split by study group 
  Cardiac 
Diagnosis 
No. of Patients % of 
Total 
Experimental Group                                Yes 
No 
Total 
6 60 
4 40 
10 100 
Control Group                                         Yes 
No 
Total 
9 69 
4 31 
13 100 
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6.5.5. Analysis of true and false event triggers 
Table 23 - Real Care true event occurrences and Figure 22 - Real Care true 
event occurrence chart show the true event types found in the Real Care 
data.  Table 25 - True events and diagnosis breakdown and Figure 24 - Event 
type leading to diagnosis bar chart then show the breakdown of true events 
that led to a diagnosis in the Real Care study 
 
Table 23 - Real Care true event occurrences 
Event Type Frequency % of 
Total 
Tachy - NCT 3 10.7 
Tachy - BCT 1 3.6 
Brady - SSS 1 3.6 
Brady - AVB 1 3.6 
Asystole 8 28.6 
AF - Tachy 3 10.7 
AF - Brady 1 3.6 
Symptom Recording - NSR 9 32.1 
APBs / VPBs 1 3.6 
Total 28 100.0 
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Figure 22 - Real Care true event occurrence chart 
 
 
False events were predominantly caused by artefacts with 12 (32%) patients 
having an artefactual recording.  The full breakdown of false events is shown 
in Table 24 and Figure 23 
 
Table 24 - Real Care false event recording frequency 
False Event Type Frequency 
% of 
Total 
No false event 8 21.6 
Artefact 12 32.4 
Undersensing 6 16.2 
Inappropriate activator use 7 18.9 
Sinus tachycardia 3 8.1 
Brief pause in AF <4.5sec 1 2.7 
Total 37 100.0 
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Figure 23 - Real care false event frequency chart 
 
 
Table 25 - True events and diagnosis breakdown 
True Event (Yes/No) Diagnosis                 Event Type Frequency % of Total 
Yes 
Yes 
Tachy - NCT 3 13.0 
Tachy - BCT 1 4.3 
Asystole 8 34.8 
AF - Tachy 2 8.7 
AF - Brady 1 4.3 
Symptom Recording - NSR 7 30.4 
APBs / VPBs 1 4.3 
Total 23 100.0 
No 
Brady - SSS 1 20.0 
Brady - AVB 1 20.0 
AF - Tachy 1 20.0 
Symptom Recording - NSR 2 40.0 
Total 5 100.0 
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Figure 24 - Event type leading to diagnosis bar chart 
 
 
6.5.6. Descriptive analysis of time to first true event 
The median time to the first true event ECG for the complete Real Care data 
was four (0 – 44) weeks.  Table 26 - Descriptive data for time to first true 
event for Real Care data shows the median, minimum and maximum time to 
first true event in weeks. 
 
Table 26 - Descriptive data for time to first true event for Real Care data 
N = 28 
Median (Weeks) 4 
Minimum 0 
Maximum 44 
 
The median time to the first true event in the experimental group data was 
four (1 - 11) weeks. The median time to the first true event in the control group 
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data was five (0 - 44) weeks.  The SPSS output showing the median, 
minimum, and maximum time to first true event ECG can be seen in Table 27 
- Time to first true event ECG split by study group. 
 
Table 27 - Time to first true event ECG split by study group 
   
Exp                                    N= 
Median (Weeks) 
Minimum (Weeks) 
Maximum (Weeks) 
13 
4 
1 
11 
Con                                   N= 
Median (Weeks) 
Minimum (Weeks) 
Maximum (Weeks) 
15 
5 
0 
44 
 
6.5.7. Primary implant indication analysis 
The primary indication for ILR implant in the Real Care data was syncope.  Of 
the 37 patients included in the study, a total of 21 had transient loss of 
consciousness (TLoC) / syncope as an indication.  Ten patients had an 
indication either solely for, or including dizzy spells.  There were 12 patients 
that had an indication for or including palpitations.  Finally one implant was 
due to vacant episodes.  The full breakdown of the implant indications can be 
seen in Table 28 - Frequency table for implant indication and  
Figure 25 - Implant indication bar chart. 
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Table 28 - Frequency table for implant indication 
Indication Frequency % of 
Total 
TLoC / Syncope 17 45.9 
Dizzy Spells 4 10.8 
Palpitations 7 18.9 
TLoC / Palpitations 1 2.7 
Dizzy Spells / Palpitations 3 8.1 
TLoC / Dizzy Spells 3 8.1 
Palpitations with Chest Pain 1 2.7 
Vacant Episodes 1 2.7 
Total 37 100.0 
 
Figure 25 - Implant indication bar chart 
 
 
6.5.8. Response to diagnosis 
The following data illustrates the response in terms of monitoring following a 
diagnosis.  It is worthwhile noting again that a diagnosis can be cardiac or 
non-cardiac, and that by non-cardiac the inference is that it is unlikely that the 
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heart is the cause of the implant indication and this does not always mean 
that a cause has been identified as would be the case in the traditional use of 
the term ‘diagnosis’.  For those that receive a cardiac diagnosis the traditional 
use of the term ‘diagnosis’ applies.  It is also worth mentioning at this point 
that ILRs are removed when a pacemaker is implanted. 
 
Analysis of the diagnosis data found that 15 (70%) of the patients that 
received a diagnosis retained their ILR for further monitoring and 7 (30%) 
patients received a pacemaker.  
 
Table 29 - Frequency table for outcome following diagnosis 
Outcome Frequency 
% of 
Total 
Pacemaker Implant 7 30.4 
Continue to monitor 8 34.8 
Pacemaker offered for symptoms - continue to monitor 1 4.3 
RF ablation / EP study - continue to monitor 1 4.3 
Medical management - continue to monitor 4 17.4 
Referred to another speciality - continue to monitor 2 8.7 
Total 23 100.0 
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Figure 26 - Frequency chart for true event response / outcome following 
diagnosis 
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6.6. Example ILR recordings from the Real Care study 
The following figures are examples of recordings made by CDDFT ILR 
patients; the figure titles will state the type and classification of the recording. 
 
Figure 27 - Artefact, false event recorded as FVT 
 
 
 
 
1 second 
1sq = 200ms 
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Figure 28 - SVT, true event 
 
 
 
 
 
 
 
 
 
1 second 
1sq = 200ms 
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Figure 29 - Sudden bradycardia 
 
 
 
 
 
 
 
 
1 second 
1sq = 200ms 
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Figure 30 - Asystole 
 
1 second 
1sq = 200ms 
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Chapter 7. Conclusions and discussion 
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In this chapter the RevEAL™ and CARElink™ (Real Care) study will be 
discussed and explored, and the conclusions presented.  In brief the main 
findings will be discussed, and then the wider results and the inferred possible 
outcomes will be discussed, followed by implications of the findings, 
limitations and their impact upon the Real Care study, putting the findings into 
practice, future research, and personal reflection. 
 
7.1. Main findings of the Real Care study 
The primary aims of the Real Care study were to see if the use of remote 
monitoring with implantable loop recorders (ILRs) could significantly reduce 
the time taken to follow-up a true event and to achieve a diagnosis with a 
robust study design. 
 
The study found that the use of remote monitoring led to a statistically 
significant reduction in time from a true event occurring to the subsequent 
follow-up, the divergence is evident at all time points in the survival curve of 
the Kaplan Meier plot (Figure 19) and 50% of patients without home 
monitoring had to wait at least an additional two weeks before follow-up (p = 
0.004) (Table 8 and Table 9).  Perhaps more importantly the median time from 
implant to diagnosis was reduced by seven weeks (p = 0.049) (Table 10 and 
Table 11).  The only three studies available and reviewed in sections 2.8 – 
2.10 (44,45,68) all stated similar findings but only the study by Drak-
Hernandez et al. (68) carried out statistical testing to verify this.  Their results 
stated a statistically significant average reduction in time to diagnosis of 204 
days (p < 0.001).  As stated in section 2.10, the study by Drak-Hernandez and 
colleagues was the most robust study to have been carried out on remote 
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monitoring of ILRs as it was the only study to have a control group.  However 
the study was neither randomised nor prospective which negatively impacted 
the robustness of the study.  The Real Care study was the first and only 
registered randomised controlled trial (RCT) with clinician blinding in the field 
of remote monitoring of implantable loop recorders to date and despite being 
underpowered the results were still statistically significant.   
 
The evidence (44,45,68) and indeed the Real Care study results in section 6.4 
look at first glance to suggest that remote monitoring is superior to 
conventional follow-up of either three-monthly intervals as in the Drak-
Hernandez et al. (68) paper or the six-monthly intervals at County Durham 
and Darlington NHS Foundation Trust (CDDFT) hospitals.  However it could 
and possibly should be argued that the median time reduction of two weeks 
for time to follow-up after a true event and seven week median reduction in 
time to diagnosis are not clinically significant.  Additionally it is also important 
to take into account the cost of the home monitoring equipment, currently 
£900 per monitor and the additional time required to follow-up patients.  There 
was no formal time in motion analysis carried out as part of the Real Care 
study but a basic calculation of the time allowed for follow-up suggested a 
three-fold increase in follow-up time.  The current CDDFT method of in-office 
follow-up (routine or ad hoc) is allocated 30 minutes per appointment.  In the 
experimental group, patients were asked to send transmissions fortnightly or 
following a symptom.  Remote follow-up appointments were allocated 20 
minutes; this included contacting the patient by telephone unless prior 
arrangements were made with the patient to send them a letter if there were 
no abnormalities.  There were 362 follow-ups carried out, 65 for the control 
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group and 297 for the experimental group.  Calculated into hours of follow-up 
time, that was 32.5 hours for control and 99 hours for experimental group 
patients.  One way that the additional time could be reduced, a method that is 
in fact being trialled on patients not involved in the Real Care study but who 
currently use the remote monitoring system, is to only contact them for an 
additional follow-up if there are any arrhythmias or manual recordings to 
discuss. 
 
Based on the median time reductions from event to follow-up and diagnosis 
alone, the above might be interpreted that the benefit of home monitoring in 
conjunction with ILRs is not as impressive as originally perceived.  That might 
not be strictly true.  Closer review of Figure 19 - Survival plot for time from true 
event to follow-up shows that even those in the experimental group that did 
not comply with the fortnightly data transmissions, never went more than five 
weeks before a true event was followed-up.  Compare that with patients in the 
control group and it shows that approximately 35% of the patients in that 
group waited between five and 24 weeks to have a true event followed-up.  
The reason for home monitoring patients not going past five weeks before 
follow-up of a true event is two-fold; firstly the study design required patients 
to transmit data on a fortnightly basis.  Secondly the patients that waited five 
weeks were a combination of patients that had true event prior to the first 
follow-up (and randomisation into the study) and non-compliant patients. It is 
possible that if all patients had been enrolled at implant the five week 
maximum wait to follow-up would have been less.  Even if routine remote 
follow-up was carried out monthly then the time to follow-up would still be 
minimal. 
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A similar picture was revealed on closer inspection of Figure 20 - Survival plot 
for time to diagnosis by study group.  The difference between median time to 
diagnosis was seven weeks but the divergence of the two groups increased at 
approximately ten weeks by which point 80% of the experimental group 
patients that received a diagnosis had received their diagnosis whereas only 
52% of the patients in the control group that received a diagnosis had done 
so.  At maximum it took 32 weeks longer for a diagnosis to be reached in the 
control group.  Taking all of the evidence into account and examining the data 
the suggestion is that remote monitoring of ILRs is not only statistically 
beneficial but that there are potentially clinically significant diagnostic time 
reductions also. 
 
Throughout this thesis, particularly throughout the results chapter (Chapter 6) 
and this section of the discussion (section  .1) the terms ‘true event’ and 
‘diagnosis’ have been widely used but not always in conjunction.  This is 
particularly confusing as not only is the median time from event to follow-up 
much shorter but also as there was a higher number of patients with a true 
event (n = 28, Table 17) than there was with patients with a diagnosis (n = 23, 
Table 18).  The explanation for number of true events not being the same as 
number of diagnoses is slightly more complex, but only slightly; in terms of 
time from event to follow-up and time to diagnosis, the starting points are 
different.  For time from event to follow-up the starting point of the measure is 
the date of the event and for time to diagnosis the starting point is the date of 
implant of the ILR.  The explanation for number of true events not being the 
same as number of diagnoses, the explanation is slightly more complex but 
only slightly.  Not all true events are considered to be clinically significant at 
  
141 
 
that time and therefore a diagnosis might not be made from such an event.  
An example of this would be a three second asystole, if the event was 
nocturnal, or occurred diurnally but in the absence of symptoms then whilst it 
might be suggestive of a cardiac problem it is not enough evidence to base a 
diagnosis on. 
 
7.2. Wider discussion of the Real Care results and inferred possible 
outcomes as a consequence of the study 
ILR device memory saturation is a potentially problematic but common finding 
during follow-up.  Saturation of the device memory occurs when artefacts, or 
undersensing / oversensing of ECG signals causes inappropriate recordings 
to overwrite previous recordings in the device memory, potentially wiping true 
event ECGs.   One of the key findings in the paper by Furukawa et al (44) was 
the reduction in device memory saturation made by false ECG detection that 
could potentially lead to a delay in diagnosis.  In their study they found 14% of 
transmissions to be saturated and they postulated that had their patients been 
on their standard follow-up pathway (three-monthly in-office checks) that the 
figure would have been around 45%.  Analysis of the Real Care data showed 
no significant difference in device memory saturation with only a seven 
percent reduction in memory saturation from 25% down to 18% in the remote 
monitoring group (p = .778).  From the analysis of the Real Care results and 
the data presented by Furukawa et al. (44), it is unlikely that remote 
monitoring of ILRs would create a truly significant reduction in device memory 
saturation without severely increasing clinical workload and service cost by 
increasing the remote transmissions to daily. 
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Before moving onto the Cox regression analysis of age and gender as 
determinants of diagnosis, it would be prudent to briefly recap the Real Care 
study participant demographics as the even distribution of age and gender is 
preferable for this Cox regression.  In brief the participant demographics show 
that 37 ILR patients had been recruited into the Real Care study.  Overall 
there were 19 male and 18 female with a mean age of 63 ± 16 years and a 
median age of 63 (36 – 89) years (Table 5).  When this is subdivided into the 
Carelink™ (e perimental) group and the control group there were ten male 
and eight female participants in the Carelink™ group with a mean age of 60 ± 
15 years and a median age of 60 (36 – 86) years.  In the control group there 
were 11 male and eight female participants with a mean age of 66 ± 16 years 
and a median age of 69 (36 – 89) years (Table 6). 
 
Cox regression analysis was used to analyse the Real Care study data with 
the aim of discovering whether age and / or gender could be used as 
predictors or determinants of diagnosis in the ILR population.  Neither age nor 
gender could be could be isolated as determinants to suggest a diagnosis 
would be achieved, but that does not give the complete story.  When age and 
gender were added, the regression suggested that the likelihood of patients 
with remote monitoring receiving a diagnosis were nearly three times higher 
(HR = 2.709, p = 0.049, Table 13) than that of patients in the control group 
despite the study groups being well matched and there being no significant 
difference between the group demographics.  However, if age group was 
added as a categorical covariate, therefore comparing all age groups (30 – 
50, 51 – 70, and over 71) against the baseline group (30 – 50 year olds) then 
the likelihood of patients with remote monitoring receiving a diagnosis 
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increased to just over three times (HR = 3.128, p = 0.028, Table 14).  This 
suggests that patients in the baseline age group of 30 – 50 year olds are 
slightly more likely to receive a diagnosis.  The problem with this data is that 
the study was not powered to address this question and the results could be 
different if larger group sizes and chance findings cannot be ruled out. 
 
When analysing the diagnostic yield of ILRs, the overall diagnostic yield for 
the Real Care data analysis was 62% (Table 18).  A diagnostic yield of 62% is 
a figure that is well in excess of the data put forward by Furukawa et al. (73) 
which included the data of nine studies.  Their calculations from the nine 
studies suggested an average diagnostic yield of 35%.  However their data 
only included cardiac diagnosis and not those in which a non-cardiac 
diagnosis is made.  When reviewing the Real Care data the cardiac diagnosis 
only yield is 41% (Table 19), still in excess of the average figure.   
 
The results of the Real Care study showed that 19% of the study patients 
received a pacemaker as a result of findings on their ILR.  This means that 
nearly half of the patients that received a cardiac diagnosis required a 
pacemaker, a fact that emphasises the move towards early use of ILRs which 
is recommended in the National Institute of Health and Clinical Excellence 
(NICE) guidelines (4) and the European Society of Cardiology guidelines (3).  
In both guidelines the diagnosis of falls and syncope is reliant upon good 
history taking and the physician being certain that the cause of the syncope is 
not cardiac.  The use of the word ‘certain’ potentially provides a loophole 
which will increase the use of other tests such as head-up tilt (HUT) or 
repeated Holter monitoring, however it is also possible that the use of ‘certain’ 
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was used intentionally to guide physicians towards thinking about referring 
patients to have an ILR therefore allowing a higher chance of diagnostic 
certainty. 
 
The Real Care analysis highlighted the shortfall in ILR implantation at CDDFT 
hospitals.  The incidence data described in section 1.4 Incidence data on 
syncope in the UK suggests that CDDFT’s implant rate of 1 0 – 200 ILRs per 
year is a significant shortfall.  Whilst the majority of the patients that receive a 
diagnosis do not have a life-threatening problem the 41% of ILR patients that 
have a cardiac diagnosis potentially do have a life-threatening condition, this 
is particularly true of the 19% of ILR patients that required a pacemaker in this 
study.  One way that has been shown to increase ILR implant rates, and to a 
lesser extent reduce misdiagnosis, is the introduction of specialist falls and 
syncope clinics or falls and syncope services and the introduction of visual 
aids to Accident and Emergency departments that recommend referral of 
patients with falls and syncope directly to the specialist service (1).  This 
pathway of referral directly to a specialist falls and syncope service could be 
extended to primary care, giving the healthcare staff in the community setting 
easy access to falls and syncope services.  Not only could this reduce the risk 
of potentially life threatening arrhythmias in cardiac syncope patients but also 
reduce the number of unnecessary tests, therefore reducing diagnostic time.  
In doing this the demand on physiology services would increase with 
additional tests and device follow–ups.  The use of remote monitoring with 
ILRs could have a role to play in the development of such services as it has 
the potential to provide a means of screening a large number of ILR patients 
in a relatively small period of time. 
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One of the insights gained from the Real Care study was that the number of 
visits to the Cardiac and Respiratory Department for ILR follow-up 
appointments could be reduced with the use of remote monitoring.  Due to the 
lack of evidence around this relatively new technology, patients that used the 
equipment in the study were still required to attend the department for follow-
up appointments at six-monthly intervals.  Having tested the equipment and 
transmission reliability there were no major issues found during the study.  
Therefore it is entirely possible that patients using the Carelink™ remote 
monitoring system could have some routine appointments removed.  
Furthermore patients that do not have remote monitoring, that contact the 
department having either made three manual recordings, or suffered implant 
symptoms are asked to attend the department for a follow-up.  In most cases 
the appointment given to these patients is an overbooking, which means that 
patients may be required to sit and wait until they can be seen or that they 
may not be able to be seen for several days.  With remote monitoring these 
checks can be done without the patient attending the department.  However, 
currently there is no payment tariff for remote monitoring of ILRs and the study 
/ department have taken on the cost of the additional checks.  Before a full 
remote monitoring clinic could be implemented there would need to be 
arrangements for funding and also time written into the Cardiac Rhythm 
Management (CRM) rota specifically for the purposes of remote monitoring 
clinics.  In part the cost and time of additional checks could be offset by the 
inclusion of extra patients.  If remote monitoring clinics were set up (in place of 
in-office clinics) using the 20 minute appointment slots used in the Real Care 
study then in the average seven and a half hour working day (excluding lunch) 
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a total of 22 follow-up appointments could be arranged.  In comparison to this 
only 15 follow-up appointments at the standard 30 minutes can be arranged. 
 
Recruitment to the Real Care study was considerably slower than anticipated, 
the issues surrounding recruitment were not entirely understood initially and 
the presumption was that this was due to protocol issues as mentioned in 
section 3.9 and the reduction from two implanting centres and a satellite 
recruiting site to one implanting centre and a satellite site.   While the protocol 
amendment (section 3.17) did increase recruitment, the study remained under 
recruited.  The decision to remove the second implanting site was made due 
to workload, staffing changes and differences in practice not allowing for 
uniformity in recruitment.  However, the implant rates achieved at the single 
implanting centre were well in excess of the number required to power the 
Real Care study and therefore the impact of this decision was felt to be 
minimal.  Before looking into the issues that were found by reviewing the files 
of those not included the recruitment figures will be recapped.  In total 185 
patients received a PIS, 148 (80%) of those were not included in the study.  
Of that 148 patients, 28 (19%) patients did not meet the inclusion criteria (this 
included ten patients that received a different ILR device) and 31 (21%) 
declined to participate.  That left 89 patients which was 48% of the overall 
number of patients that received a PIS, not included in the study.  The 
question then was, why?  Various reasons were speculated, the main one 
being increased clinical pressures and restraints on time.  Whilst increasing 
clinical pressures and time restraints could account for a small percentage of 
the figure it was unacceptable this was the only reason.  A review of the 
patient files heralded some interesting findings.  The main reason for patients 
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not being included was down to a clinical decision made by the Physiologist or 
the implanting Physician that it would not be fair to the patient to ask them to 
use the additional equipment.  That decision could be seen as a potential 
source of selection bias, however patient care is at the heart of everything we 
do and as practitioners we sometimes feel that it is unethical to ask patients to 
carry out extra work with extra equipment when they are already struggling to 
comprehend the equipment that is required for their care.  It was clearly 
documented in 59 (66%) of the patients that they struggled to understand the 
use of the patient activator and were therefore not suitable for the Real Care 
study.  Additionally 18 (20%) of the 89 patients reported that they had not yet 
read the PIS at the time of implant (or initial five week check in the case of 
pre-protocol amendment patients) a subsequent follow-up call was made (in 
some cases at the next check) to ask the patients if they would like to take 
part and they reported that they still had not read the information.  The 
remaining 12 (14%) patients had nothing documented regarding the Real 
Care study and had all been under conventional care for in excess of three 
months.  Due to the lack of documentation and the length of follow-up that 
had already occurred, no attempt was made to recruit these patients. 
 
The issues surrounding recruitment did however raise an interesting point.  
Technology is not everyone’s strongpoint and had recruitment gone smoothly 
it may not have been realised that remote monitoring might not suit every 
individual.  When the recruitment data was reviewed, it was suggestive that 
the current model is not suitable for all patients.  One possible solution to this 
would be for the newest device to be added to the Medtronic™ Reveal™ 
family, the Reveal™ LINQ™.  The new ILR has wireless connectivity and as 
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such removes the need for patient interaction.  Unfortunately, the cost of the 
device to CDDFT hospitals is between £1700 and £2200 depending on the 
amount purchased while the Reveal™ XT that is currently used is £1000.  The 
current tender makes the Carelink™ home monitoring equipment a free of 
charge device to CDDFT and the cost is considerably different.  Another 
possibility would be to offer home monitoring to patients at a 10 to 12 week 
follow-up as it is after this point that the survival curves for median time from 
true event to follow-up (Figure 19) and median time to diagnosis (Figure 20) 
start to diverge considerably and patients have had time to adjust not only to 
having the ILR implanted but also time to get used to the use of the activator.  
 
7.3. Implications of the findings 
The analysis carried out on not only the Real Care data but also the study as 
a whole suggest that remote monitoring of ILRs is going to become a valuable 
tool in the future but that current technology, and the infrastructure within 
CDDFT hospitals Cardiology Services do not allow for a full adoption 
approach towards remote monitoring.  With that said, the currently available 
technology alongside minimal changes such as reducing the number of in-
office follow-ups, a better selection and education process for remote 
monitoring, and a more refined process for dealing with remote follow-up in 
terms of when to contact patients has the potential within CDDFT hospitals to: 
 
1. Be good for patients by reducing hospital visits and improving clinic 
availability therefore giving faster access to all patients. 
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2. Reduce diagnostic time for ILR patients meaning that they can receive 
treatment or be referred to the correct specialism faster. 
 
3. Reduce clinic workload but increase the number of patients reviewed. 
 
There are unfortunately potential negative implications too suggesting that: 
 
1. Remote monitoring is not currently suitable for all ILR patients due to 
the requirement of patient interaction with the equipment. 
 
2. Patients need to be selected carefully; some of the patients requiring 
an ILR are older, frail, or unable to fully understand the importance or 
the use of the equipment. 
 
The reason the above points are referred to as potentially negative is that they 
can also be turned quite easily into positives.  Technology is moving forward 
and as the newer devices such as the Medtronic Reveal™ LINQ™ become 
more widely available remote monitoring will become more suitable for all ILR 
patients.  As for the second point, ignoring the possibility of everyone getting 
the newer technology in the future, there are changes that can be made now 
to explore the use of home monitoring fully in the patient group that have thus 
far been excluded.  Many of the patients that are very frail, or cannot 
understand the equipment have carers or relatives that visit frequently, or 
attend follow-up appointments with the patient.  This can be logistically 
challenging and sometimes stressful.  Perhaps it would therefore be more 
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appropriate for the relative / carer of these patients to be taught how to use 
the equipment and for these patients to be monitored remotely. 
 
7.4. Limitations of the Real Care study 
As with all studies the Real Care study was not without its limitations.  The 
lack of recruitment led to the first limitation in that only 50% of the patients 
required for the study to be at full power (90%) were recruited.  Due to the fact 
that the study still found significant reductions in time from event to follow-up 
and time to diagnosis the effect of this limitation is believed to be minimal.  
Recruitment and recruitment issues are discussed in detail in sections 7.2 and 
7.5 in this chapter. 
 
A further limitation to this analysis (not the study overall) is that some patients 
had not reached full follow-up time due to the staggered entry of patients 
inherent in this type of study. 
 
7.5. Impact of limitations upon the results 
The impact of these limitations upon the Real Care study’s results is open to 
interpretation; while the results could well be underpowered the information 
gained was still statistically significant and could be seen as a valuable step 
forward in the field of remote monitoring of ILRs.  There is also the argument 
that the exclusion of so many patients could be a source of selection bias.  
The effect however would be minimal on the comparison data due to the 
randomisation process and the groups remaining significantly similar.  
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The lack of a complete follow-up period for some patients in the study could 
possibly have an impact upon the results but the analysis of this data and 
previous studies is suggestive that the trend would continue and that the 
results would either be similar or improve the superiority of remote monitoring. 
 
It is worth mentioning again at this point that despite being underpowered the 
Real Care study still demonstrated a statistically significant reduction in both 
time from true event to follow-up and time to diagnosis using a robust design 
which until this study had not been done. 
 
7.6. Putting the findings into practice 
In their paper on the use of remote monitoring with ILRs Arrocha et al (2010) 
stated that remote monitoring could be burdensome to staff (45).  While no 
formal time in motion study was carried out as part of this thesis, both the 
author and other members of the Cardiac Rhythm Management (CRM) team 
agree that in its current format whereby patients are contacted following their 
data transmission and essentially have a complete follow-up over the 
telephone, or a letter is dictated or typed requires an allowance of time that 
with current staffing levels would be difficult to sustain, particularly if the 
numbers of end users was to increase.  It was previously mentioned in this 
chapter a possible solution or minimisation tool for this problem is being 
trialled, patients that are using remote monitoring but were not part of the Real 
Care study are only being contacted after a transmission if there are any 
symptom recordings or any arrhythmias to discuss, and if merged with an 
improved selection and initiation process, remote monitoring would still be an 
impressive tool for reducing diagnostic time and improving patient care. 
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In order to maximise the effect of remote monitoring, several changes would 
be required in CDDFT hospitals.  These changes would need to be managed 
effectively for the full potential of remote monitoring to be reached.  Some of 
the initial changes to services that would allow for a robust remote monitoring 
service have already been mentioned in this chapter; firstly the selection 
criteria and the timing of introduction of the equipment would need to be 
decided.  One possible suggestion from reviewing the available data and the 
results of the Real Care study is that the idea of remote monitoring could be 
introduced on the day of implant and then patients could have the equipment 
explained and given at the five-week follow-up.  This would serve several 
purposes.  Firstly this approach would allow patients to consider their options 
and could reduce an element of fear that can surround technology.  Secondly 
it would be the ideal opportunity to suggest that the patient brings a relative or 
carer to the appointment.  This in turn would allow patients that are currently 
deemed unable to use the equipment to be included.  This approach would 
also allow for the five-week follow-up to have an increased appointment time 
where patients have an opportunity to get a full demonstration of the 
equipment and have any questions or issues discussed.  Patients would be 
asked to send their remote monitoring recordings as per the Real Care study 
(fortnightly or following symptoms) and would be advised that contact would 
only be made if a manual recording was present or if the recording needed to 
be discussed.  The next step would be to create clinics or an allocation of time 
within clinics dedicated to remote follow-up.  This could incorporate all 
remotely monitored devices and system administration (currently an adhoc 
process) not just ILRs therefore ensuring that time is utilised effectively.  
However, in order to make these changes and potentially switch to a remote 
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monitoring service with minimal physical patient attendances to the clinic, 
discussions need to be had around the introduction of a tariff that will cover 
the cost of the service and some work will need to be carried out with the staff 
on change management. 
If services such as specialist falls and syncope services or improved care 
pathways were introduced that potentially increased implant rates, then 
services would require alterations just to meet demand.  The possibility of 
increasing the availability of available services has already been discussed in 
this section and could easily be incorporated into plans to expand and 
improve patient care for falls and syncope.  
 
Whilst not a finding of the Real Care study, the research process and in 
particular the literature review that I undertook as part of this thesis, has 
directly led to changes in the programming methodology of ILRs at Darlington 
Memorial Hospital where I am currently a cardiac physiologist.  Previously it 
was common practice to set the bradycardia detection limit to only record 
rates ≤ 30bpm.  After reviewing the literature, it was put forward by the author 
of this thesis that this was too stringent and allowed the team to potentially 
miss significant bradycardias.  This point was accepted by the clinical team 
and the bradycardia detection rate is now set to record rhythms at a rate of ≤ 
40bpm in line with the ISSUE classification (69) as standard. 
 
7.7. Future research 
Whilst the evidence supports the use of remote monitoring of ILRs there are 
still areas that require further work.  This study became underpowered due to 
recruitment; the suggestions made in section 7.6 Putting the findings into 
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practice introduced a possible way for more ILR patients to be included.  This 
would allow for a larger trial to be conducted.  Currently the results of this 
study, while believed to be transferable are only tested on the CDDFT ILR 
population; a larger multicentre trial would be able to prove whether or not the 
results were fully transferable. 
 
There is also scope for some qualitative research related to ILRs and remote 
monitoring, do patients feel that they are getting the best care if they are no 
longer required to be seen every six-months? Is there any impact upon quality 
of life (QoL) between those patients that have a conventional follow-up 
pathway and those that have remote monitoring?  The evidence (44,45,68) 
including this study suggests that remote monitoring has a role in patient care 
but do the patients believe it adds any benefit to their care?  The QoL and 
additionally psychological research could also be broadened into just the 
impact of ILRs.  A search of PubMed, Medline, Ovid, Allied and 
Complementary Medicine (AMED), Excerpta Medica Database (EMBASE), 
Health Management Information Consortium (HMIC), British Nursing Index 
(BNI), PsycInfo, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Health Business Elite and Google returned no hits relating purely 
to ILR patients and QoL or psychological impact of having an ILR and waiting 
to be symptomatic.  When you consider that patients on conventional care are 
implanted with a device, and then essentially told to go away and have 
another symptom (predominantly syncope), there is potential for this to impact 
upon their life.  Anecdotally when speaking to ILR patients in follow-up clinics 
many of the patients report that they do not like to go anywhere alone, or in 
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severe cases do not want to leave the house at all for fear of having a 
syncopal episode. 
 
Another area of future qualitative research could look at the clinical staff 
perspectives of remote monitoring, do they think it is diminishing care by 
taking the patient contact away from the job, or do they think it improves the 
patient care pathway?  Do clinical staff think remote monitoring is an important 
step towards the future or just a gimmick that will become too time consuming 
to be of use?  
 
7.8. Personal reflection 
When reflecting on the journey undertaken to reach this point, it is easy to 
dismiss elements that while key at the time, seem to pale in comparison to the 
greater issue of recruitment.  However most of the elements were entwined 
with recruitment at the time and it is only now, on reflection, that realisation 
can fully occur.  Recruitment was initially seen as a constant embarrassment 
and always a point that rose at trial meetings and supervisory meetings.  It 
was only at the point of analysis that the importance of the under recruitment 
was highlighted.  Time was spent attempting to right a wrong that was in 
reality an important factor relating to the technology used in the Real Care 
study.  It showed that the team actively involved in the study were enthusiastic 
about the technology and the change it could bring with it, but emphasised the 
fact that not everyone is the same. People are individuals and not all 
individuals embrace change in the same way.  A simple and well known 
premise but one that is easily overlooked, as told to me many years ago 
during training, a phrase that sticks with me is “Always remember to go back 
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to the basics”.  At the time and for many years I associated it with diagnostics 
and if I was troubleshooting a problem would look at the basics first and not 
jump straight in to the more technical possibilities.  It is only now that the full 
meaning of those words is becoming clear.  As a researcher it is easy to 
embrace technology and even to embrace change with the thought at the 
back of the mind that just because something has always been done a 
particular way it is not necessarily the best way.  The basics of human 
emotion and thought however mean that not everyone is curious about 
change and that an innate fear of change or a desire for sticking to what is 
known, or comfortable is preferential.  The approach towards the Real Care 
study was created and reviewed by researchers of like minds. Whilst there 
was diversity within the team, reflection would suggest the inclusion of those 
that are openly sceptical of change or research in order to create a better 
balance although this would probably have slowed things down.  Perhaps if 
the trial was to be carried out again it would be beneficial for sessions to be 
held with the doctors, physiologists and nurses on change management and 
to have sessions with the patients to introduce them to the technology in a 
relaxed environment rather than in a clinic setting or directly after they have 
been through a procedure. 
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Chapter 8. Concluding remarks 
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In this final chapter the concluding remarks of the thesis are presented as a 
summary of the main conclusions, limitations and next steps. 
  
8.1. Main Conclusions 
The first conclusion to be drawn from the analysis of the REveAL™ and 
CARElink™ (Real Care) study is that remote monitoring can be effective in 
reducing both diagnostic time and the time taken to detect a true event ECG 
for implantable loop recorder (ILR) patients.  However further discussion is 
required as to whether the reduction is clinically significant in the majority of 
cases. 
 
The second conclusion which in all likelihood is actually more important than 
the first as it has potential to dramatically influence the first; technology is not 
every patients’ strongpoint, and that in the larger population of ILR patients 
the currently available mainstream method of remote monitoring for ILR 
patients is not an attractive option.  Once the technology of the Reveal™ 
LINQ™ with its wireless capability is available to all patients, the full potential 
of remote monitoring could be realised. 
 
Finally, until the new technology becomes available to all, a new process of 
patient selection and management could maximise the impact of remote 
monitoring on diagnostic time reduction whilst increasing patient uptake of the 
service. 
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8.2. Limitations 
One of the biggest limitations became one of the most important findings in 
the Real Care study.  Recruitment initially thought to be predominantly a 
process issue in fact uncovered a possible failing of the technology believed 
to be suitable for the majority of patients.  Not all patients adapt well to new 
technology and there has to be a line at which we do not ask more of the 
patients.  During the review of patients not included in the Real Care study it 
became clear that a high percentage of our patients struggled with the use of 
technology that was designed to aid their care.  In this case it was when 
explaining the use of the ILR activator to the patient following the implant of 
their ILR that highlighted the problem.  Sometimes the things we believe to be 
simple are in reality only simple to those that understand the process already. 
 
8.3. Next steps 
Moving forward there is a potential need for a larger multicentre trial with a 
qualitative aspect to review patient benefit in terms of quality of life (QoL) and 
perceived benefit of care.  In terms of reducing diagnostic time and relieving 
pressure on clinics at County Durham and Darlington NHS Foundation Trust 
(CDDFT) hospitals there is a good level of evidence to suggest that with 
correctly managed minimal changes to the current care pathway, a reliable 
and safe alternative to the current regime could be introduced successfully.  In 
fact changes have already begun to take effect due to the findings of this 
study. 
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Appendix 1 - Real Care Protocol 
 
 
 
  
173 
 
 
 
 
  
174 
 
 
 
 
 
  
175 
 
  
176 
 
  
177 
 
  
178 
 
  
179 
 
  
180 
 
  
181 
 
  
182 
 
  
183 
 
  
184 
 
  
185 
 
  
186 
 
  
187 
 
  
188 
 
  
189 
 
  
190 
 
  
191 
 
  
192 
 
  
193 
 
  
194 
 
  
195 
 
  
196 
 
  
197 
 
  
198 
 
  
199 
 
  
200 
 
  
201 
 
  
202 
 
  
203 
 
  
204 
 
  
205 
 
  
206 
 
  
207 
 
 
  
208 
 
Appendix 2 - Patient Information Sheet (PIS) 
 
 
 
  
209 
 
 
 
 
 
  
210 
 
 
 
 
 
  
211 
 
 
 
 
 
  
212 
 
 
 
 
 
  
213 
 
 
 
 
 
  
214 
 
 
 
 
 
  
215 
 
Appendix 3 - Real Care consent form 
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Appendix 4 - Real Care GP letter 
 
 
 
  
217 
 
Appendix 5 - Real Care follow - up form 
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Appendix 6 - Medtronic Carelink™ consent form 
 
